

CURRICULUM VITAE

CAROLINA L. HAASS-KOFFLER, PHARMD, PHD

CONTACT

121 South Main Street
Providence, RI 02912
Brown University



Cellular: 415-519-1385
Telephone: 401-863-6624
Fax: 401-863-6697
Email: carolina_haass-koffler@brown.edu
Website: [Clinical Neuroscience Lab](#)
Brown profile: [Carolina L Haass-Koffler](#)
Twitter  : [@Carolinja2](#)
ORCID  : 0000-0002-5634-5679

TABLE OF CONTENT

TABLE OF CONTENT.....	2
EDUCATION.....	3
POSTGRADUATE TRAINING.....	3
HONORS AND AWARDS.....	4
MILITARY SERVICE.....	5
ACADEMIC APPOINTMENTS.....	5
HOSPITAL APPOINTMENTS AND CERTIFICATION.....	5
SERVICE TO UNIVERSITY AND DEPARTMENT.....	6
UNIVERSITY COMMITTEES.....	6
DEPARTMENT COMMITTEES.....	6
REVIEWER ROLES.....	7
REVIEWER FOR GRANT PROPOSAL.....	7
REVIEWER FOR FACULTY CANDIDATES FOR PROMOTION.....	8
REVIEWER FOR PEER-REVIEWED SCIENTIFIC JOURNALS.....	8
SOCIETY AND CONFERENCE RESPONSIBILITIES.....	9
EDITORIAL RESPONSIBILITIES.....	10
MEMBERSHIP IN SOCIETIES.....	10
PUBLICATION LIST.....	10
PEER-REVIEWED ORIGINAL PUBLICATIONS.....	10
PEER-REVIEWED SYSTEMATIC AND NARRATIVE REVIEW.....	13
EDITORIALS AND RESEARCH HIGHLIGHTS.....	14
BOOK CHAPTERS.....	15
NON-PEER REVIEWED PUBLICATIONS.....	15
PUBLICATIONS SUBMITTED AND UNDER REVIEW.....	16
ENTREPRENEURSHIP AND TECHNOLOGY TRANSFER.....	16
PATENTS AND PATENT APPLICATIONS.....	16
FDA INVESTIGATIONAL NEW DRUGS (IND).....	17
INTERVIEWS FOR MASS-MEDIA.....	17
INVITED PRESENTATIONS AND SYMPOSIA.....	18
NATIONAL.....	18
INTERNATIONAL.....	20
GRANTS.....	21
CURRENT GRANT SUPPORT.....	21
PENDING GRANT SUPPORT.....	23
COMPLETED GRANT SUPPORT.....	24
INDUSTRY APPOINTMENTS AND PARTNERSHIPS.....	27
UNIVERSITY MENTORING AND TEACHING ROLES.....	27
MENTORING, SUPERVISING AND THESIS COMMITTEE ROLES.....	27
FACULTY MENTOR.....	29
CONFERENCE MENTOR.....	29
MENTOR AND TEACHING TRAINING PROGRAM.....	29
TEACHING.....	30
ACADEMIC TEACHING ROLE.....	30
HOSPITAL TEACHING ROLES.....	32
<i>ADDENDUM: MENTORING AND SUPERVISING ROLES</i>	33
LIST OF POSTERS WITH MENTEES (*Mentee).....	37
NATIONAL.....	37
INTERNATIONAL.....	42

Carolina L. Haass-Koffler, Pharm.D. Ph.D.

EDUCATION

Undergraduate University of California, Berkeley, CA, US
Bachelor of Science (B.S.), Chemistry, 05/2002
Mentor: Evan Williams, Ph.D.

Advanced
Degrees University of California, San Francisco (UCSF), CA, US
Doctor of Pharmacy (Pharm.D.)
Pharmaceutical Sciences Pathway, 03/2009
Mentor: Selena Bartlett, Ph.D.

 University of Camerino (UNICAM), ITALY
Doctor of Philosophy (Ph.D.)
Chemical and Pharmaceutical Sciences and Biotechnology, 05/2022
Mentor: Roberto Ciccocioppo, Ph.D.

POSTGRADUATE TRAINING

Postdoctoral
Fellowship Ernest Gallo Clinic and Research Center
Medication Development
Neuroscience Department
University of California, San Francisco (UCSF)
Specialization: Substance Use Disorder, 05/2009-08/2012
Mentor: Selena Bartlett, Ph.D.

Clinical
Fellowship Clinical Pharmacology and Experimental Therapeutics
School of Medicine
University of California, San Francisco (UCSF)
Specialization: Neuropsychopharmacology, 09/2009-04/2012
Mentor: Leslie Floren, Pharm.D.

NIAAA
Postdoctoral
Fellowship NIH/NIDA/NIAAA T-32 Postdoctoral Fellow
Center for Alcohol and Addiction Studies (CAAS)
Brown University
Specialization: Human Laboratory Studies and Clinical Trials, 09/2013-03/2016
Mentors: Robert Swift, M.D., Ph.D. and Lorenzo Leggio, M.D., Ph.D.

HONORS AND AWARDS

- 1994 Italian Red Cross: Medal Commissioner International Association
- 1997 Ministry of Defense, Italy: Medal for United Nation Mission in Somalia
- 2007 University of California, San Francisco (UCSF), Drug Awareness Award: University of Utah, School on Alcoholism and Other Drug Dependencies, California Society of Health-Systems Pharmacists
- 2008 UCSF: Research Creativity Award: Pathway Project Award Vince Isnardi, 2009 Dean's Award for Outstanding Pharmaceutical Sciences Pathway Project Award, School of Pharmacy
- 2012 National Institutes of Health/National Institute Drug Abuse (NIH/NIDA): Travel Award Behavior, Biology, Chemistry; Translational Research Addiction, University Texas
- 2012 American Association for the Advancement of Science (AAAS): Postdoctoral Program for Excellence in Science,
- 2012 UCSF: Strategic Opportunities Exploratory Award
- 2012 JALA & JBS Art of Science Contest: *Science, religion and art all strive for their own answers...but all are alike in awe of the mysteries of life*
- 2013 European Society Biomedical Research Alcoholism (ESBRA), Warsaw, Poland: Poster Award
- 2013 Brown University, Center for Alcohol and Addiction Studies: Research Excellence Award
- 2014 National Institutes of Health/ National Institute on Alcohol Abuse and Alcoholism, (NIH/NIAAA): International Travel Award, Alcoholism and Stress: Framework for Future Treatment Strategies, Volterra, Italy
- 2015 European Society Biomedical Research Alcoholism (ESBRA): NIH/NIAAA R13 International Travel Award, Valencia, Spain
- 2016 American Society Clinical Psychopharmacology: New Investigator Award, Scottsdale, AZ
- 2017 NIH/NIAAA: Young Investigator Award Alcoholism and Stress, Volterra Conference, Italy
- 2017 Brown University: Faculty Travel Volterra, Italy
- 2017 Brown University, Center for Alcohol and Addiction Studies: Rohsenow Pilot Project Award
- 2017 NIDA-NIAAA: Early Career Investigator Showcase (ECIS), Frontiers in Addiction Research, Washington, DC
- 2018 Brown University, School of Public Health: Dean's Award for Excellence in Research Collaboration
- 2018 NIAAA R13: International Travel Award, International Society Biomedical Research Alcoholism (ISBRA), Kyoto, Japan
- 2018 Brown University: Faculty Travel Award Kyoto, Japan
- 2019 Winter Brain Research Conference (WBRC): Travel Fellowship, Aspen, CO
- 2019 American College of Neuropsychopharmacology (ACNP): Travel Award, Orlando FL
- 2019 ACNP: Elected to Associate Member
- 2022 Brown University, Board of Fellows: Master of Arts *ad eundem*
- 2023 Brown University Innovator Award for the US patent: 11,278,527: *Composition and Methods for the Modulation of Corticotropin Releasing Factor Binding Protein and the treatment of Alcohol Use Disorder*
- 2023 Brown University: Faculty Travel Award Volterra, Italy
- 2023 Massachusetts Institute of Technology (MIT)/Brown University: Faculty Founder Initiative
- 2024 Brown University: Biomedical Innovation to Impact (BBII), Steven J. Massarsky Biomedical Research Innovation Award
- 2025 ACNP: Elected to Member

2025 Washington University, Equalize Startups Award: program that seeks to equalize the pathway for academic women who want to commercialize their innovations

MILITARY SERVICE

1992 - 1996 Italian Red Cross, Auxiliary Military Italian Forces, Rome, Italy, Army Hospital, Celio, Orthopedic, Trauma and Emergency Medicine, Lieutenant Nurse
1993 United Nations Operation Somalia II (UNOSOM II), Mogadishu, Johar, Emergency Field Nurse
1994 - 1995 Italian Air Force, Rome, Italy, Lieutenant in charge, Air Mobile Search and Rescue (S.A.R.)
1994 International Relief Missions, Rwanda, Emergency Field Nurse
1995 Mission Council of the Italian Government, Serbo-Bosnian War Emergency Field Nurse

ACADEMIC APPOINTMENTS

2013 - 2021 Northeastern University, Boston, MA, Bouvé College of Health Sciences, Pharmacogenetics and Pharmacogenomics; Position: Lecturer
2015 - 2022 National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD; Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, Position: Special Volunteer
2016 - 2017 Brown University, Providence, RI, Warren Alpert Medical School, Department of Psychiatry and Human Behavior; Position: Assistant Professor in research track
2016 - 2017 Brown University, Providence, RI, School of Public Health, Department of Behavioral and Social Sciences; Position: Assistant Professor in research track
2016 - 2017 Brown University, Providence, RI, Center for Alcohol and Addiction Studies; Position: Assistant Professor in research track
2017 - 2021 Brown University, Providence, RI Warren Alpert Medical School, Department of Psychiatry and Human Behavior; Position: Assistant Professor in research scholar track
2017 - 2021 Brown University, Providence, RI, School of Public Health, Department of Behavioral and Social Sciences; Position: Assistant Professor in research scholar track
2017 - 2021 Brown University, Providence, RI, Center for Alcohol and Addiction Studies; Position: Assistant Professor in research scholar track
2021 – pres. Brown University, Providence, RI Warren Alpert Medical School, Department of Psychiatry and Human Behavior; Position: Associate Professor in Research Scholar track
2021 – pres. Brown University, Providence, RI, School of Public Health, Department of Behavioral and Social Sciences; Position: Associate Professor in Research Scholar track
2021 – pres. Brown University, Providence, RI, Center for Alcohol and Addiction Studies; Position: Associate Professor in Research Scholar track
2021 – pres. Brown University, Providence, RI, Carney Brain Institute for Brain Science; Position: Associate Professor in Research Scholar track

HOSPITAL APPOINTMENTS AND CERTIFICATION

2006 - 2007 California Society of Health-Systems Pharmacists: University of California, San Francisco (UCSF) Drug Awareness Coordinator
2007 - 2009 San Francisco General Hospital (SFGH), Department Public Health, Community Behavioral Health Services (CBHS): Drug Information Intern

2008 - 2009	UCSF: Advanced Pharmacy Practice Experience <ul style="list-style-type: none"> • UCSF Parnassus, General Medicine, Acute Care Inpatient • SFGH, Anticoagulation Clinic, Family Health Clinic, Outpatient • United States Coast Guard, Federal Pharmacy and Ambulatory Care
2009 - 2011	SFGH: Medication Use and Safety Subcommittee (MUSS)
2014	Butler Hospital: Structured Clinical Interview (SCID) for DSM-IV and DMS-5 training
2015 - pres.	American Medical Technologists: Registered Phlebotomy Technician (#2756154)
2017 - pres.	Rhode Island Department Health (RIDOH): Interagency on Overdose Research
2018 - pres.	Providence Veterans Affairs Medical Center: Without Compensation Appointment (WOC)
2019	Substance Abuse and Mental Health Services Administration (SAMHSA): Opioid Overdose Training, Opioid Response Network

SERVICE TO UNIVERSITY AND DEPARTMENT

UNIVERSITY COMMITTEES

2018 - pres.	Brown University, Providence, RI; Institutional Review Board (IRB), Primary Member
2020 - pres.	Brown University, Providence, RI; Institutional Biosafety Committee (IBC), Member
2021	Brown University, Providence RI: Institutional Review Board (IRB) Subcommittee for Magnetic Resonance Imaging (MRI) Inform Consent Addendum
2022	Brown University, Providence RI: Institutional Review Board (IRB) Subcommittee for Magnetic Resonance Imaging (MRI) Inform Consent for minors
2022	Brown University, Providence RI: Office of the Vice President for Research (OVPR) Reviewer for Seed Award proposal
2022	Brown University, Providence, RI; Institutional Biosafety Committee (IBC), member of a subcommittee on the use of a replication incompetent SARS-CoV-2 model
2022 - pres.	Brown University, Providence RI: Institutional Review Board (IRB) Subcommittee on Equity and the Recruitment of Non-English-Speaking Participants
2023 – pres.	Brown University, Division of Biology and Medicine, Lifespan and Care New England Hospital. The Brown Innovation and Research Collaborative for Health (BIRCH): Clinical Trial Committee member
2024 – pres.	Brown University, Providence, RI: Institutional Review Board (IRB) Use of Investigational Tobacco Products (ITP) Sub-Committee
2024 – pres.	Bryant University, Providence RI, external faculty mentor on National Science Foundation (NSF)

DEPARTMENT COMMITTEES

2010 - 2012	University of California, San Francisco (UCSF), Ernest Gallo Clinic and Research Center: Imaris Neuroscience microscopy/software interface, manager, administrator and technical support
2010 - 2012	UCSF, Clinical Pharmacology and Experimental Therapeutics Fellowship Program: Selection Committee
2016 - 2021	Brown University, Department of Behavioral and Social Health Sciences, School of Public Health: Master admissions committee

2017 - 2022	Brown University, Department of Behavioral and Social Health Sciences, School of Public Health: Doctoral Admissions Committee
2020 - 2022	Brown University, School of Public Health Dean's Awards in Excellence in Research Collaboration: Recipient and Reviewer
2021 - 2024	Brown University, Neuroscience Graduate Program (NSGP): Doctoral NSGP Recruitment
2022 - 2024	Brown University, Neuroscience Graduate Program (NSGP): Doctoral Admissions Committee
2022 - 2024	Brown-NIH Graduate Program Partnership (GPP): Doctoral Admissions Committee

REVIEWER ROLES

REVIEWER FOR GRANT PROPOSAL

National Institutes of Health (NIH)

2017-2020	Center for Scientific Review (CSR) - Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section (NPAS) (tree meetings/year): <i>ad hoc</i> Reviewer
2018	National Institute Alcohol Abuse Alcoholism (NIAAA) - Special Emphasis Panel, Collaborative Research at the Clinical Center (U01) ZAA1 DD (44): Reviewer
2018	CSR - Networks and Behavior in Psychiatric Disorders, Special Emphasis Panel/Scientific Review Group 2018/1 ZRG1 BDCN-C(90): Reviewer
2018	CSR - Epigenomes and Connectomes in Psychiatric Disorders, Special Emphasis Panel/Scientific Review Group 18/10 ZRG1 BDCN-C(55) R PAR-158: Reviewer
2018	CSR - Special Emphasis Panel/Scientific Review Group 2019/01 ZRG1 NPAS-W(06): Reviewer
2019	NIAAA - Special Emphasis Panel, Collaborative Research at the Clinical Center (U01) ZAA1 DD (11), RFA AA19-005 Medication Development: Reviewer
2020	NIAAA - Special Emphasis Panel NIAAA FRA AA-20-07 Medication Development for alcohol use disorder (AUD) and Alcohol-Related Organ Damage (AROD): Reviewer
2020	CSR - Neuroimaging of Addiction, NPAS Special Emphasis Panel/Scientific Review Group 2020/10 ZRG1 NPAS-W (07) S: Reviewer
2020 - 2022	CSR - NPAS: Standing Member (tree meetings/year)
2021	CSR - Certificate Eliminating Bias in peer review
2021	NIAAA - Special Emphasis Panel, ZAA1 GG (32) L NIAAA Individual Fellowships (F30, F31, F32): Reviewer
2023	NIAAA AA-3 Clinical, Treatment and Health Services Research Review Study Section Meeting: Co-Chair
2023	NIAAA - Special Emphasis Panel/Scientific Review Group 2024/01 ZAA1 GG (32) L Individual Fellowships (F30, F31, F32): Reviewer
2024 - 2025	NIDA - Core Center of Excellence Grant Program (P30) and (P50): Reviewer
2024	NIAAA - Special Emphasis Panel/Scientific Review Group 2024/01 ZAA1 GG (32) 1 Individual Fellowships (F30, F31, F32): Chair
2024	NIDA - Psychedelics Treatment Research in Substance Use Disorder ZDA1 BSW-M (O1) R: Acting Chair
2024	NIAAA - Special Emphasis Panel/Scientific Review Group 2025/01 ZAA1 GG (32) 2 Individual Fellowships (F30, F31, F32): Chair

Department of Defense (DOD)

- 2017 Consortium Award peer review panel of the FY217 Alcohol and Substance Abuse Disorders Research Program (ASADRP) - Congressionally Directed Medical Research Programs (CDMRP): Scientific Reviewer
- 2021 Consortium Award peer review panel of the FY21 Alcohol and Substance Abuse Disorders Research Program (ASADRP) - Congressionally Directed Medical Research Programs (CDMRP): Scientific Reviewer

Other Institutions: National and International

- 2016 - 2020 European Foundation for Alcohol Research (ERAB) - regular grant reviewer (annual review)
- 2018 Université Catholique de Louvain, Belgium - Scientific reviewer
- 2025 Morgan State University, Reviewer for Pilot Grants Program

REVIEWER FOR FACULTY CANDIDATES FOR PROMOTION

- 2012 Department of Psychiatry, University California, San Francisco (UCSF), CA
- 2017 Department of Psychiatry, University of Illinois, Chicago, IL
- 2023 Department of Psychiatry, Harvard University, MA
- 2024 Department of Psychiatry, University of California, San Diego (UCSD), CA

REVIEWER FOR PEER-REVIEWED SCIENTIFIC JOURNALS

1. *Addictions* (N:2)
2. *Addiction Biology* (N: 11)
3. *Addictive Behaviors* (N: 2)
4. *Alcohol* (N: 9)
5. *Alcohol and Alcoholism* (N: 70)
6. *Alcohol: Clinical and Experimental Research (ACER)* (N: 24)
7. *American Journal Addiction Medicine* (N: 2)
8. *American Journal of Psychiatry* (N: 4)
9. *American Psychology Association, Division 28, Psychopharmacology and Substance Abuse*
10. *American Psychology Association, Division 50 Addiction Psychology*
11. *Behavioral Brain Research* (N:1)
12. *Biological Psychiatry* (N: 9)
13. *Biological Psychology* (N: 2)
14. *Brain Behavior and Immunity* (N: 2)
15. *CNS Drugs* (N: 3)
16. *CNS Spectrum* (N. 1)
17. *Current Psychopharmacology* (N: 2)
18. *Drugs* (N. 1)
19. *Drug and Alcohol Dependences* (N: 9)
20. *Drug and Alcohol Dependence Report* (N: 2)
21. *European Journal of Internal Medicine (EJIM)* (N: 8)

22. *Experimental and Clinical Psychopharmacology* (N: 2)
23. *Frontiers in Psychiatry, Endocrinology, Psychology* (N: 7)
24. *Journal of Neuroscience Research (JNR)* (N: 2)
25. *Journal of Studies on Alcohol and Drugs* (N: 1)
26. *Molecular Psychiatry* (N: 4)
27. *Nature* (N: 5)
28. *Nature Communications* (N: 1)
29. *Neuropharmacology* (N: 4)
30. *Neuropsychopharmacology* (N: 5)
31. *Neuropsychiatric Disease and Treatment* (N: 1)
32. *Neuroscience and Behavior Review* (N: 2)
33. *Neuroscience, Psychology and Psychiatry, Elsevier, Academic Press* (N: 1)
34. *Neurotherapeutics* (N: 5)
35. *PLOS ONE* (N: 4)
36. *Psychopharmacology* (N:2)
37. *Psychiatry Research* (N: 2)
38. *Psychoneuroendocrinology* (N: 10)
39. *Science, American Association Advancement of Science (AAAS)* (N: 4)
40. *Translational Psychiatry* (N.1)

SOCIETY AND CONFERENCE RESPONSIBILITIES

- 2018 - pres. International Society for Biomedical Research on Alcoholism (ISBRA): Member of the Education Committee
- 2019 - pres. Volterra Conference, Alcoholism and Stress, A Framework for future treatment strategies: Member of the Scientific Committee
- 2019 - 2024 American College Neuropsychopharmacology (ACNP): Associate Member
- 2020 - 2023 ACNP: Member of the Program Committee
- 2021 - 2022 ACNP: Hot Topics/Data Blitz Subcommittee
- 2021 ACNP: Scientists Engagement Task Force
- 2021 ACNP: Mentor to Travel Awardee, Puerto Rico, PR
- 2022 RSA: Member of the scientific program committee
- 2022 ACNP: Data Blitz co-chair, Phoenix, AZ,
- 2022 ACNP: Mentor to Travel Awardee, Phoenix, AZ
- 2023 Winter Brain Research Conference (WBRC): Mentor to Travel Awardee, Snow Bird, UT
- 2023 RSA: Panelist, Grant Skills Workshop
- 2024 RSA: co-Chair (Clinical) Scientific Program Committee for the annual 2024 RSA meeting
- 2024 Gordon Conference, Translational Neuroscience of Alcohol: Integration of Basic and Clinical Research, poster judge
- 2024 RSA: Panelist, Grant Skills Workshop
- 2024 – pres. RSA: Member of the Membership Committee
- 2025 – pres. ACNP: Member
- 2025 – 2027 ACNP: Member of the Scientific Communications Committee

- 2025 College on Problems of Drug Dependence (CPDD) conference: Panelist, *What's your best Pitch? The Value of Entrepreneurship and Startup Creation Training for Substance Use Disorder Researchers Workshop*, June 2025
- 2025 RSA: Member of the Scientific Program Committee

EDITORIAL RESPONSIBILITIES

- 2017 - 2020 Psychopharmacology, Frontiers in Psychiatry, Reviewer Editorial Board
- 2018 - 2019 Neurotherapeutics, Guest Editor, Special issue on *Translational Research in the Neurobiological Mechanisms of Alcohol and Substance Use Disorders*.
- 2019 - pres. Alcohol and Alcoholism, Editorial Board

MEMBERSHIP IN SOCIETIES

1. American Association for the Advancement of Science (AAAS)
2. American Association of Pharmaceutical Scientists (AAPS)
3. American College Neuropsychopharmacology (ACNP)
4. American Chemical Society (ACS)
5. American Pharmacists Association (APhA)
6. American Society Clinical Psychopharmacology (ASCP)
7. California Society of Health-Systems Pharmacists (CHSP)
8. European Society for Biomedical Research on Alcohol (ESBRA)
9. International Society for Biomedical Research on Alcohol (ISBRA)
10. Research Society for Alcohol (RSA)
11. Society for Neuroscience (SfN)
12. Student National Pharmaceutical Association (SNPhA)

PUBLICATION LIST

(*Mentee, #Equal contribution)

PEER-REVIEWED ORIGINAL PUBLICATIONS

1. Simms JA, **Haass-Koffler CL**, Bito-Onon J and Bartlett SE. *Mifepristone in the Central Nucleus of the Amygdala Reduces Yohimbine Stress-Induced Reinstatement of Ethanol seeking.* Neuropsychopharmacology 2012. PMID: 22048462; PMC3280651
2. **Haass-Koffler CL**, Naeemuddin M and Bartlett SE. *An Analytical Tool that Quantifies Cellular Morphology changes from Three-Dimensional Fluorescence Images.* Journal of Visualized Experiments 2012. PMID: 229551512; PMC3486772 [VIDEO](#)
3. Chatterjee S, Santos N, Holgate J, **Haass-Koffler CL**, Hopf W, Kharazia V, Lester L, Bonci A and Bartlett SE. *The $\alpha 5$ Subunit Regulates the Expression and Function of $\alpha 4^*$ -Containing Neuronal Nicotinic Acetylcholine Receptors in the Ventral-Tegmental Area.* PLoS One 2013. PMID: 23869214; PMC3712017
4. **Haass-Koffler CL** and Kenna GA. *Bacchus by Caravaggio as the visual diagnosis of Alcohol Use Disorder (AUD) from the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).* Frontiers in Psychiatry 2013. PMID: 23964247; PMC3737464. **Recipient: best performing articles in Frontiers**

5. Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Vuittonet C, Fricchione S, Brickley M, Beaucage K, **Haass-Koffler CL** and Leggio L. *Ondansetron reduces naturalistic drinking in non-treatment seeking alcohol dependent subjects with LL 5'-HTTLPR alleles: a laboratory study.* Alcoholism: Clinical and Experimental Research 2014. PMID: 24773166; PMC4047179
6. Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Fricchione S, Brickley M, Beaucage K, **Haass-Koffler CL** and Leggio L. *Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: Exploratory findings.* Alcohol 2014. PMID: 25212749; PMC4163011
7. Aoun EG, Lee MR, **Haass-Koffler CL**, Swift MR, Addolorato G, Kenna GA and Leggio L, *Relationship between the thyroid axis and alcohol craving.* Alcohol and Alcoholism 2014. PMID: 25433251; PMC4266183
8. **Haass-Koffler CL**, Leggio L, Davidson D and Swift RM. *The Effect of Idazoxan on Human Alcohol Intoxication and Alcohol Pharmacokinetics.* Alcoholism: Clinical and Experimental Research 2015. PMID: 25833022; PMC4384190
9. **Haass-Koffler CL**, Aoun EG, Kenna GA, de la Monte SM, Swift RM and Leggio L. *Exogenous intravenous ghrelin administration decreases leptin serum level and increases alcohol craving.* Translational Psychiatry, 2015. PMID: 26418274; PMC5545639. **Selected Article: featured on the [NIDA Science Highlights](#)**
10. Kenna GA, **Haass-Koffler CL**, Zywiak WH, Edwards SM, Brickley MB, Swift RM and Leggio L. *Role of the alpha-1 Blocker Doxazosin in Alcohol Dependence: a Proof-of-Concept Randomized Double-Blind Placebo-Controlled Trial.* Addiction Biology 2016. PMID: 26037245; PMC4668239
11. **Haass-Koffler CL**, Giovenco DE*, Lee MR, Zywiak WH, de la Monte SM, Kenna GA, Swift RM and Leggio L. *Serum insulin levels are reduced by intravenous ghrelin administration but do not correlate with alcohol craving in alcohol dependent individuals,* International Journal of Neuropsychopharmacology, 2016. PMID: 27207912; PMC5091823
12. **Haass-Koffler CL**, Henry AT*, Melkus G, Simms JA, Naemmuddin M, Nilsen CK, Schwandt ML, Hodgkinson CA, Magill M, Lasek AW, Momenam R, Bartlett SE, Swift RM, Bonci A, and Leggio L. *Defining the role of Corticotropin Releasing Factor Binding Protein in alcohol consumption,* Translational Psychiatry 2016. PMID: 27845775, PMC3434418 **Recipient: New Investigator Award Volterra, Italy**
13. **Haass-Koffler CL**, Goodyear K*, Zywiak WH, Magill M, Wallace PM*, Eltinge S*, Long VM*, Jayaram-Lindström N, Swift RM, Kenna GA, Leggio. *Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin* Drug Alcohol Depend 2017. PMID: 28551590. PMC5534374 **Selected Article in the New England Journal Medicine ([NEJM](#)) [Journal Watch](#)**
14. **Haass-Koffler CL**, Goodyear K*, Long VM*, Loche A, Cacciaglia R, Swift RM, and Leggio L. *Phase I randomized clinical trial for the safety, tolerability and pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers,* Eur J Pharm Sci 2017. PMID: 28778464; PMC5776031
15. **Haass-Koffler CL**, Goodyear K*, Long VM*, Tran HH*, Loche A, Cacciaglia R, Swift RM, Leggio L, *Dataset for Phase I clinical trial for safety and tolerability of GET 73 in single and repeated doses including preliminary pharmacokinetics parameters.* Data in Brief, 2017. PMID: 29214202, PMC5712048
16. Aoun EG*, Jimenez V, Vendruscolo LF, Walter NAR, Barbier E, Ferulli A, **Haass-Koffler CL**, Darakjian P, Lee, MR, Addolorato G, Heilig M, Hitzemann R, Koob GF, Grant KA, and Leggio L. *Relationship between the aldosterone - mineralocorticoid receptor pathway and alcohol drinking: preliminary translational findings across rats, monkeys and humans* Molecular Psychiatry 2018. PMID: 28461696 PMC5668213 **Selected Article: featured on the [NIAAA press](#) release and selected as an [NIH-wide press](#) and [Selected Article: NIDA paper of the month](#)**
17. **Haass-Koffler CL**, Goodyear K*, Zywiak W, Kenna GA, Leggio L and Swift RM, *Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study.* Alcohol and Alcoholism, 2018. PMID: 29281033; PMC5913672

18. **Haass-Koffler CL**, Goodyear K*, Loche A, Long VM*, Cacciaglia R, Swift RM, and Leggio L. *Administration of the Metabotropic Glutamate Receptor Subtype 5 Allosteric Modulator GET 73 With Alcohol: A Translational Study in Rats and Humans* Journal Psychopharmacology 2018. PMID: 29361897; PMC7014573
19. Goodyear K*, **Haass-Koffler CL**, Chavanne D, Opioid use and stigma: the role of gender, language and precipitating events Drug and Alcohol Dependence 2018. PMID: 29499554; PMC6097242
20. **Haass-Koffler CL**, Goodyear K*, Zywiak W, Kenna GA, Leggio L and Swift RM, Corrigendum: *Aripiprazole and Topiramate on Free-Choice Alcohol Use* Alcohol and Alcoholism, 2018. PMID: 29718153; PMC6016693
21. **Haass-Koffler CL**, Long VM*, Farokhnia M, Magill M, Kenna GA, Swift RM and Leggio L. *Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: results from a double-blind, placebo-controlled human laboratory study* Neuropharmacology 2019. PMID:31310775; PMC6745267 **Selected Article: presented by Dr. George Koob at the 152nd Meeting of the National Advisory Council on Alcohol Abuse and Alcoholism**
22. Tunstall BJ, Lorrai I, McConnell SA, Gazo KL, Zallar LJ, Di Guglielmo G, **Haass-Koffler CL**, Repunte-Canonigo V, Koob GF, Vendruscolo LF, Sanna PP. *Probenecid Reduces Alcohol Drinking in Rats: is Pannexin1 a Novel Therapeutic Target for Alcohol Use Disorder?* Alcohol and Alcoholism 2019 PMID: 31535696; PMC6751410
23. **Haass-Koffler CL**, Piacentino D, Li X, Long VM*, Lee M, Kenna GA and Leggio L. *Differences in sociodemographic and alcohol-related clinical characteristics between treatment seekers and non-treatment seekers and their role in predicting outcomes in the COMBINE study for alcohol use disorder* Alcoholism: Clinical and Experimental Research 2020 PMID: 32997422; PMC7722230 **Selected Article: ACER Article of Public Interest (API)**
24. **Haass-Koffler CL**, Perciballi R*, Brown ZE*, Zywiak WH, Lee M, Kurtis J, Swift RM, and Leggio L. *Relationship between cotinine levels and peripheral endogenous concentrations of oxytocin, β -endorphin and orexin in individuals with both alcohol and nicotine use disorders* The American Journal on Addictions 2021 PMID: 32488890; PMC7944578
25. **Haass-Koffler CL**, Souza RS*, Wilmott J*, Aston ER, Song JH. *A combined alcohol and smoking cue-reactivity paradigm in people who drink heavily and smoke cigarettes: preliminary findings* Alcohol and Alcoholism 2021 PMID: 32984874; PMC7768621 **Selected Article: Alcohol and Alcoholism Highlights issue 56-1 2021**
26. Stopponi S, Fotio Y, Cifani C, Li H, **Haass-Koffler CL**, Cannella N, Demopoulos G, Gaitanaris G, Ciccocioppo R. *Andrographis paniculata and its main bioactive ingredient andrographolide decreases alcohol drinking and seeking in rats through activation of nuclear PPAR γ pathway* Alcohol and Alcoholism 2021 PMID: 33401299; PMC7906876
27. Farokhnia M, Abshire KM, Hammer A, Saravakumar A, Cobbina E, You ZB, **Haass-Koffler CL**, Lee MR, Akhlaghi F, Leggio L. *Neuroendocrine response to exogenous ghrelin administration, combined with alcohol, in heavy-drinking individuals: Findings from a randomized, double-blind, placebo-controlled human laboratory study* Int J Neuropsychopharmacology 2021. PMID: 33560411; PMC8278796 **Featured on the NIDA IRP website as the July 2021 Paper of the Month**
28. Zywiak, WH, **Haass-Koffler, CL**, Olinsky, A, Cavicchio, L, & Ciliberto, DJ. *Some Alcohol-Related Consequences for Women May Signal an Escape from Interpersonal Violence*. Special issue: Gender and Women's Studies and Health Care Advances in Applied Sociology 2021, 11, 177-184
29. Goodyear Chavanne K*, Vasaturo-Kolodner T*, Kenna GA, Swift RM, Leggio L and **Haass-Koffler CL** *Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for participants with alcohol use disorder.* The American Journal of Drug and Alcohol Abuse (AJDAA) 2021 PMID: 34582281; PMC8711071
30. Monnig MA, Treloar Padovano H, Sokolovsky A, DeCost G, Aston E, **Haass-Koffler CL**, Szapary C, Moyo P, Avila J, Tidey J, Monti, PM, and Ahluwalia J. *Associations of Substance Use with Behavioral*

- Adherence to CDC Guidelines for COVID-19 Mitigation* Journal of Medical Internet Research 2021 PMID: 34591780; PMC8582757
31. **Haass-Koffler CL**, Perciballi R*, Magill M, Loche A, Cacciaglia R, Leggio L. and Swift RM *An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder* Psychopharmacology 2021 PMID: 34731268; PMC8865311
 32. Varodayan FP, Patel RR, Matzeu A, Wolfe SA, Curley DE*, Khom S, Gandhi P, Rodriguez L, Bajo M, D'Ambrosio S, Sun H, Kerr TM, Gonzales RA, Leggio L, Natividad LA, **Haass-Koffler CL**, Fardon M, Roberto M. *The amygdala noradrenergic system is compromised with alcohol use disorder* Biol Psychiatry 2022 PMID: 35430085; PMC9167785 **Selected Article: presented by Dr. George Koob at the 2022 Meeting of the National Advisory Council on Alcohol Abuse and Alcoholism**
 33. Lunerti V; Hongwu L; Benvenuti F; Shen Q; Domi A; Soverchia L; Di Martino RMC; Bottegoni G; **Haass-Koffler CL**, Cannella N. *The multitarget FAAH inhibitor/D3 partial agonist ARN15381 decreases nicotine self-administration in male rats.* Eur J Pharmacol 2022 PMID:35690082
 34. **Haass-Koffler CL**, Francis TC*, Gandhi P, Patel R, Naemmuddin M, Nilsen CK, Bartlett SE, Bonci A, Vasile S, Hood B, Suyama E, Hedrick MP, Smith LH, Limpert AS, Roberto M, Cosford ND and Sheffler DJ. *Development of a High-Throughput Screen to Identify Novel Modulators of the Corticotropin Releasing Factor Binding Protein.* Society for Laboratory Automation and Screening Discovery (SLAS) 2022, PMID: 36210051; PMC9762412 **Featured as Paper of the Week by the Sanford Burnham Discovery**
 35. Monnig M, Clark SE, Avila JC, Sokolovsky A, Treloar Padovano H, Goodyear K, Aston ER, **Haass-Koffler CL**, Tidey J, Ahluwalia JS and Monti PM. *COVID-19-Related Stressors and Clinical Mental Health Symptoms in a Northeast US Sample.* International Journal of Environmental Research and Public Health, 2023, PMID:36674123; PMC9858791
 36. **Haass-Koffler CL**, Magill M, Cannella N, Brown JC, Aoun EA, Cioe PA, Sinha R, Swift RM, Ciccocioppo R, Leggio L. *Mifepristone as a pharmacological intervention for stress-Induced alcohol craving: a human laboratory study.* Addiction Biology 2023 PMID: 37369125
 37. Soliman P*, Amaefuna I*, Gully JB* **Haass-Koffler CL**. *Evaluating the Readability of Online Patient Facing Resources for Alcohol Use Disorder.* Alcohol 2024 PMID: 37661000
 38. Eaton E[#], Capone C[#], Gully BJ*, Brown ZE*, Monnig M, Worden M, Swift RM, **Haass-Koffler CL**. *Design and Methodology of the First Open-Label Trial of MDMA-Assisted Therapy for Veterans with PTSD and Alcohol Use Disorders: Considerations for a Randomized Controlled Trial.* Contemporary Clinical Trials Communications, 2024 PMID: 39262902
 39. Gully B[#], Brown ZE[#], Hornbacher R*, Brown JC, Back, S, McCance-Katz EF, Swift RM, **Haass-Koffler CL**. *Oxytocin reduces noradrenergic-induced opioid-like withdrawal symptoms in individuals on opioid agonist therapy* Biol Psychiatry: Global Open Science, 2024 PMID: 39534517
 40. Hornbacher R*, Gully B*, Brown ZE*, Brown JC, Magill M, Cioe PA, Swift RM, Sanna PP, **Haass-Koffler CL**. *Probenecid as a potential new pharmacotherapy for alcohol use disorder: a randomized placebo-controlled alcohol interaction trial.* Alcohol: Clinical and Experimental Research, 2024 PMID: 39472130
 41. Salazar-Gómez AF, Bagiaty A, Adeyema H, **Haass-Koffler CL**, Breazeal C. *The MIT SUD Ventures Program: Entrepreneurship Training for Researchers in STEM and Beyond.* Conf Proc Front Educ Conf IEEE Xplore PMID: 40093859; PMCID: 11908454
 42. Rhew R*, Brown ZE*, Gully BJ*, Gunn RL, Douval C, **Haass-Koffler CL**. *Evaluating the age of individuals who are seeking treatment for substance use disorder in a community-based recovery center.* (Alcohol Alcoholism, (in press))

PEER-REVIEWED SYSTEMATIC AND NARRATIVE REVIEW

43. **Haass-Koffler CL** and Bartlett SE. *Stress and Addiction: Contribution of Corticotropin Releasing Factor System in Neuroplasticity*, Special Topic *Frontiers*, Frontiers In Molecular Neuroscience 2012. PMID: 22973190; PMCID: PMC3434418
44. **Haass-Koffler CL** Leggio L, and Kenna GA. *Pharmacological Approaches to Reducing Craving in Alcohol Use Disorders*, CNS Drugs 2014. PMID: 24573997; PMC3990000
45. Vuittonet CL, Halse M, Leggio L, Fricchione S, Brickley M, **Haass-Koffler CL**, Tavares T, Swift RM and Kenna, GA. *Pharmacotherapy for Alcoholic Patients with Alcoholic Liver Disease*. American Journal of Health-System Pharmacy 2014. PMID: 25027533; PMC4170837
46. **Haass-Koffler CL**, Akhlaghi, F, Swift RM, Leggio L. *Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?* Journal of Psychopharmacology 2017. PMID: 28093021; PMC5768306
47. **Haass-Koffler CL**, Swift RM and Leggio L. *Noradrenergic targets in Alcohol Use Disorder, invited to contribute Special Issue focuses on Promising Alcohol Addiction Targets* Psychopharmacology, 2018. PMID:29460163; PMC995154
48. **Haass-Koffler CL**. *Role of Corticotropin Releasing Factor Binding Protein in the stress system: a strange case of Dr. Jekyll and Mr. Hyde? Invited Review as Young Investigator Awardee, Volterra Conference, Alcohol*, 2018 PMID: 29510883; PMC5899053
49. Goodyear Chavanne K* and **Haass-Koffler CL** *Opioid craving in human laboratory settings: a review of the challenges and limitations*, Invited Review for Special Issue: Neurobiological Targets in Translational Addiction Research, Neurotherapeutics 2019 PMID: 31650431; PMC7007448
50. **Haass-Koffler CL**, Perciballi R*. *Alcohol Tolerance in Human Laboratory Studies for Medications Development to treat Alcohol Use Disorder*, Alcohol and Alcoholism 2020 PMID: 31950152; PMC7082491
51. **Haass-Koffler CL**, Cannella N and Ciccocioppo R. *Translational dynamics of alcohol tolerance between preclinical models and human laboratory studies*, Special Issue on: Advancing the Translation between Clinical and Preclinical Models of Individual Differences in Vulnerability to Substance Use Disorders, Experimental and Clinical Psychopharmacology 2020 PMID:32212746; PMC7390637
52. Curley DE*, Webb A, Sheffler DJ, **Haass-Koffler, CL**. *Corticotropin releasing factor binding protein as a novel target to restore brain homeostasis: lessons learned from alcohol use disorder research*. Frontiers in Behavioral Neuroscience, section Motivation and Reward 2021 PMID: 34912198; PMC8667027
53. Curley DE*, Vasaturo-Kolodner T*, Cannella N, Ciccocioppo R and **Haass-Koffler CL**. *Yohimbine as pharmacological probe for alcohol research: a systematic review in humans and rodents*. Neuropsychopharmacology 2022 PMID:35760866; PMC9556614
54. Gully JB*, Eaton E*, Capone C* and **Haass-Koffler CL**. *Treating Post Traumatic Stress Disorder and Alcohol Use Disorder comorbidity: current pharmacological therapies and Future of MDMA-integrated Psychotherapy*. J Psychopharmacology 2023 PMID: 38009477
55. Nelson MJ*, Soliman P*, Rhew R*, Cassidy RN, **Haass-Koffler CL**. *Disruption of Circadian Rhythms Promotes Alcohol Use*. Alcohol and Alcoholism 2024 PMID: 38123479 preregistered osf.io/azf4m
56. Soliman P*[#], Curley DE*[#], Eaton E, Capone C, **Haass-Koffler CL**. *The Use of Placebo in Randomized Controlled Trials Involving Psychedelic Assisted Therapy: A Systematic Review of Challenges and Methodology*. Psychopharmacology 2024 PMID: 38683460

EDITORIALS AND RESEARCH HIGHLIGHTS

(all by invitation and peer-reviewed)

57. **Haass-Koffler CL** and Schank JR, *Neurobiological Targets in Translational Addiction Research*, Editorial *Use Disorders*, Neurotherapeutics 2020 PMID: 31965552; PMCID: PMCID7007449
58. Portis SM*, **Haass-Koffler CL**. *New Microglial Mechanisms Revealed in Alcohol Use Disorder: How Does that Translate?* Invited Commentary Biological Psychiatry 2020 PMID:33213701; PMCID: PMCID7909747

59. **Haass-Koffler CL.** *Protein Tyrosine Phosphatase β/ζ and alcohol use disorder: A Commentary* Alcoholism: Clinical and Experimental Research 2020 PMID:32343842; PMCID: PMCID7486965
60. Brown ZE*, Portis SM*, Vasaturo-Kolodner T*, Fleig C, Swift RM, **Haass-Koffler CL.** *Randomized controlled trials for alcohol use disorder during the COVID-19 pandemic* Alcohol 2021 PMID: 33434615; PMCID: PMC7832637
61. **Haass-Koffler CL** and Sheffler DJ. *Neuroscience targets and human studies: future translational efforts in the stress system.* Neuropsychopharmacology 2023 PMID: 36210051
62. **Haass-Koffler CL** *Utilizing precision medicine to treat Alcohol Use Disorder: A commentary on the $\alpha 1$ receptor antagonist.* Alcohol: Clinical and Experimental Research 2023 PMID: 36852535

BOOK CHAPTERS

1. **Haass-Koffler CL** and McCance-Katz EF. Lowinson & Ruiz's (Eds), Substance Abuse: A Comprehensive Textbook, Fifth Edition, Section 7: Management of Associated Medical Conditions, 53: *Medication Interactions*. Lippincott Wilkins, 2011; JAMA 307(17):1868-1869. doi:10.1001/jama.307.17.1868 2012
2. **Haass-Koffler CL** and McCance-Katz EF. Principles of Addiction Medicine, 6th Edition, Chapter 8: *The Pharmacology of nonalcoholic Sedative Hypnotics*, American Society Addiction Medicine (ASAM) edited by Miller S, Rosenthal R, Fiellin D, and Saitz R, 2018
3. **Haass-Koffler CL** and McCance-Katz EF. Essentials of Addiction Medicine, 6th Edition, Chapter 8: *The Pharmacology of Nonalcoholic Sedative Hypnotics*, American Society Addiction Medicine (ASAM) edited by Miller S, Rosenthal R, Fiellin D, and Saitz R, 2019
4. McCance-Katz EF and **Haass-Koffler CL.** Principles of Addiction Medicine, 7th Edition, Section 2: Pharmacology, Chapter 10: *The Pharmacology of Nonalcoholic Sedative Hypnotics*, American Society Addiction Medicine (ASAM) edited by Miller S, Rosenthal R, Saitz R, Tetrult J, Levy S and Saxon A, 2024
5. McCance-Katz EF and **Haass-Koffler CL.** Essentials of Addiction Medicine, 7th Edition, Section 2: Pharmacology, Chapter 10: *The Pharmacology of Nonalcoholic Sedative Hypnotics*, American Society Addiction Medicine (ASAM) edited by Miller S, Rosenthal R, Saitz R, Tetrult J, Levy S and Saxon A, 2024

NON-PEER REVIEWED PUBLICATIONS

6. **Haass-Koffler CL** and Gasper JJ. *Metabolic syndrome in patients treated with the second-generation antipsychotic*, Department Public Health, Community Behavioral Health Services, SFGH 2007
7. **Haass-Koffler CL.** *Formulary review: Angiotensin II Type 1 Receptor Antagonist*, Pharmacy & Therapeutics Committee, Department of Public Health, Laguna Honda Hospital 2008
8. **Haass-Koffler CL** and Gasper JJ. *Case Report: Pharmacokinetics of buprenorphine SL by alternative routes*, Department Public Health, Community Behavioral Health Services, SFGH 2008
9. **Haass-Koffler CL** and Gasper JJ. *Benzodiazepine withdrawal*, Department Public Health, Community Behavioral Health Services, SFGH 2008
10. **Haass-Koffler CL** and Gasper JJ. *Fentanyl TD tolerance*, Department Public Health, Community Behavioral Health Services, SFGH 2008
11. **Haass-Koffler CL** and Gasper JJ. *Drug-drug interaction between antiretroviral therapy and psychoactive drugs*, Department Public Health, Community Behavioral Health Services, SFGH 2008
12. **Haass-Koffler CL** and Gasper JJ. *Case report: Schizophrenia & varenicline (Chantix)*, Department Public Health, Community Behavioral Health Services, SFGH 2008
13. **Haass-Koffler CL** and Gasper JJ. *Stress and activation of κ -opioid*, Department Public Health, Community Behavioral Health Services, SFGH 2008

14. **Haass-Koffler CL** and Gasper JJ. *Clinical assessment of patients treated with clonazepine*, Department Public Health, Community Behavioral Health Services, SFGH 2008
15. **Haass-Koffler CL** and Gasper JJ. *Guidelines for physicians in psychiatric hospitals: Effectiveness, toxicity and drug interactions of psychotropic medications*, Department Public Health, Community Behavioral Health Services, SFGH 2009
16. **Haass-Koffler CL** and Leggio L. *Doxazosin: a new treatment for alcohol use disorder*. Editorial, Rivista di Alcologia: 31, 1, 2017, Firenze: Centro Alcologico Regionale Toscano, 2017
17. **Haass-Koffler CL**, Perciballi R*, Brown ZE*, Swift RM and Leggio L. *When clinical practice precedes clinical research: A case study of personalized addiction medicine* Editorial, Rivista di Alcologia: 41, 1, 2020, Firenze: Centro Alcologico Regionale Toscano, 2020
18. Perciballi R* and **Haass-Koffler CL**. *Il target noradrenico per lo sviluppo delle farmacoterapie per l'alcolismo*, Medicina delle Dipendenze Alcol: Nuove e vecchie frontiere (invited review), MDD 42, 2021

PUBLICATIONS SUBMITTED AND UNDER REVIEW

1. Fariha R*, Rothkopf E, **Haass-Koffler CL**, Tripathi A, *Opioid Quantification via Microsampling Techniques to Assess Opioid Use in Human Laboratory Studies* (Scientific Reports, under second review)
2. Miller EA*, Capone C, Eaton E, Swift RM, **Haass-Koffler CL**. *Psychedelics for alcohol use disorder: a narrative review with candidate mechanisms of action*. (CNS Drugs, invited review)
3. **Haass-Koffler CL**, Kashyap B, Gully BJ, Nambiar SS, Hornbacher R, Foster SL, Silberman Y, Swift, RM, Hanson LH, Frey WH II, *Intranasal insulin for the treatment of alcohol use disorder: Design and methodology of an alcohol interaction randomized controlled trial*. (Contemporary Clinical Trial, under review)
4. Ranney L, Capone C, Eaton E, Swift RM, **Haass-Koffler CL**. *Development of Active Placebo for MDMA-assisted therapy randomized controlled trials*. (in preparation)

ENTREPRENEURSHIP AND TECHNOLOGY TRANSFER

- | | |
|------|---|
| 2022 | NIH/NIDA UE5 DA056914 Award: <i>Program on Entrepreneurship and Innovation for Biomedical Product Development for Substance Use Disorder</i> (PI: Breazeal; Subaward PI: Haass-Koffler) |
| 2023 | Brown University Innovator Award US patent: 11,278,527: <i>Composition and Methods for the Modulation of Corticotropin Releasing Factor Binding Protein and the treatment of Alcohol Use Disorder</i> |
| 2023 | Massachusetts Institute of Technology (MIT)/Brown University: <i>Faculty Founder Initiative Award</i> |
| 2024 | Brown University: Biomedical Innovation to Impact (BBII), <i>Steven J. Massarsky Biomedical Research Innovation Award</i> |
| 2025 | Washington University, <i>Equalize Startups Award</i> : program that seeks to equalize the pathway for academic women who want to commercialize their biomedical innovations |
| 2025 | Massachusetts Institute of Technology (MIT): Sloan School of Management, <i>Negotiation Analysis</i> |

PATENTS AND PATENT APPLICATIONS

1. Bartlett SE, Bonci A, **Haass-Koffler CL**, Naeemuddin M. GC052P (61/166,632): *Chimera compositions and uses thereof* (filed April 3, 2009)

2. Bartlett SE, Bonci A, **Haass-Koffler CL**, Naeemuddin M. GC053P (61/243,437): *Ion channel compositions and uses thereof* (filed November 17, 2009)
3. Bartlett SE, Bonci A, **Haass-Koffler CL**, Naeemuddin M. GC054P (61/250,480): *Dedifferentiated cell compositions and uses thereof* (filed October 9, 2009)
4. Bartlett SE, Bonci A, **Haass-Koffler CL**, Naeemuddin M GC055P (61/261,981): *Assays for intracellular processes* (filed November 17, 2009)
5. **Haass-Koffler CL** (PCT/US2019/049498) 2023: *Composition and Methods for the Modulation of Corticotropin Releasing Factor Binding Protein and the treatment of Alcohol Use Disorder* Serial # 18/486,973 - Filed 10/13/23
6. **Haass-Koffler CL** and McCance-Katz (63/508,236): *Methods and compositions for the treatment of drug overdose* (filed June 14, 2023; U.S. Patent Application No. 18/742,945). Innovation@Brown Showcase 2023 Top 10 Innovations
7. Cosford NDP, Sheffler DJ, Raveendra-Panickar D, Hutchinson JH, **Haass-Koffler CL**. *Tetrazole and Quinazolinone Disruptors of CRFBP-CRFR2*. Serial # 63/585,745 Filed 9/27/23 - Lead by Sanford Burnham Prebys Medical Discovery Declaration and Assignment for the subject patent application 4/24/2024

FDA INVESTIGATIONAL NEW DRUGS (IND)

1. **IND121984**: mifepristone and yohimbine, [NCT02243709](#) (Completed 2022)
2. **IND135570**: oxytocin and yohimbine, [NCT04051619](#), [NCT04071119](#) (Completed 2023)
3. **IND147824**: probenecid, [NCT04218357](#) (Completed 2024)
4. **IND165005**: 3,4-methylenedioxymethamphetamine (MDMA), [NCT05943665](#) (Active, open label trail)
5. **IND168417**: insulin, [NCT05988632](#) (Active)
6. **IND175490**: 3,4-methylenedioxymethamphetamine (MDMA) (Pre-IND, randomized controlled trial)

INTERVIEWS FOR MASS-MEDIA

1. **BROWN DAILY HERALD**, the interview on the Award of the Center of Biomedical Research Excellence (COBRE) Award for the Center for Addiction and Disease Risk Exacerbation (CADRE): [\\$12.5 million grant funds new substance abuse research](#) by Emilia Sagaityte (published on September 2019)
2. **INDY** (The College Hill Independent) the interview on rising of fentanyl crisis in the US: [The Rise of King Ivory, how fentanyl become one of the most lethal drug in America](#) by Gaya Gupta (published on November 2020)
3. **THE SCIENTIST**, the [Interview](#) by Marcus Banks on the article published on [Nature Metabolism](#) (March 2021): [Brain ethanol metabolism by astrocytic ALDH2 drives the behavioural effects of ethanol intoxication](#) by Jin, Yang, Zhu, Xu, Chen, Wang, Lin Cinar, Pawlosky, Zhang, Xiong, Gao, Koob, Lovinger and Zhang.
4. **BROWN DAILY HERALD**, the interview by Anna Kim on the Office of the Vice President of Research (OVPR) Award: [2022 OVPR Seed Awards fund research by faculty](#) for the study: *Safety, feasibility, and acceptability of MDMA-assisted therapy for the treatment of co-occurring posttraumatic stress disorder and alcohol use disorders in combat veterans* (published on March, 2022)
5. **BROWN SCHOOL OF PUBLIC HEALTH CONTINUUM**, the interview by Carl Dimitry on the first study with MDMA at Brown University: [Could MDMA-assisted Therapy Successfully Treat Veterans with PTSD?](#) (published on March, 2022)
6. **MIT NEWS**, [A new educational program for scientists working on substance use disorder](#), by Stefanie Koperniak, MIT Open Learning (published on February 8, 2023)

7. **MIT NEWS**, [This MIT Bootcamp shook everything upside down and has given me the spirit of innovation](#), (published on March 5th 2024)
8. **MONITOR IN PSYCHOLOGY**, American Psychological Association, by Heather Stringer (published on March 6, 2024)
9. **NEWS FROM BROWN**, New study: [Can MDMA-assisted therapy help military veterans with PTSD and alcohol use?](#) By Katie Liesener, Communications Manager, Department of Psychiatry and Human Behavior (published on April 30, 2024)
10. **CHANNEL 10 NBC NEWS WJAR**. [Brown University study explores MDMA therapy for veterans with PTSD, alcohol issues](#) by Barbara Morse (May 13, 2024)
11. **BROWN SCHOOL OF PUBLIC HEALTH**, Humans in Public Health Podcast. [A psychedelic pathway toward PTSD recovery](#). Interview by Megan Hall (July 11th, 2024)
12. **MIT NEWS**, [3 Questions: What does innovation look like in the field of substance use disorder?](#) By Mariah Rawding, MIT Open Learning (September 11, 2024)
13. **BROWN SCHOOL OF PUBLIC HEALTH**, [Unlocking the Potential of MDMA](#) by Carly Dimitry (September 30, 2024)
14. **YAHOO NEWS**, [Can weight loss drugs help you cut back on drinking? A new study shows their effect on alcohol cravings.](#) by Rebecca Corey (February 12, 2025)
15. **DIE TAGESZEITUNG**, (German Newspaper) Lena Schega (2/21/2025)

INVITED PRESENTATIONS AND SYMPOSIA

NATIONAL

1. Presentation: *Abuse of prescription drugs*, Walgreen's Pharmacy, Daily City, CA, 2006
2. Presentation: *Too Busy To Live, Role of Schedules and Stress, Stroke and Cardiovascular Disease*, Health Now Forum, Mill Valley, CA, 2010
3. Presentation: *The C-Terminal Fragment of Corticotropin Releasing Factor Binding Protein (CRF-BP) potentiates CRF-Mediated CRF-Receptor 2 α (CRF-R2 α) signaling*. Behavior, Biology, Chemistry: Translational Research in Addiction, University of Texas, Health Center, San Antonio, TX, 2012
4. Presentation: *Novel Method to interrogate Corticotropin Releasing Factor Binding Protein (CRFBP) in the CNS*. Tufts University, Behavioral Core Neuroscience Research Center, Medford, MA, 2012
5. Presentation: *Pharmacological treatments for alcoholism: recent translational and clinical findings*, NIH, NIAAA and NIDA, Clinical Center, Bethesda, MD, 2015
6. *Pharmacological treatments for alcoholism: recent translational and clinical findings* UCONN Health, Alcohol Research Center, University of Connecticut, Farmington, CT, 2015
7. Symposium: *On the role of feeding peptides in alcoholism: recent clinical findings. Part of the symposium: Going with Your Gut: Appetitive Hormones and the Regulation of Substance Use*, American College on Neuropsychopharmacology (ACNP) Hollywood, FL, December, 2015; abstract in [Neuropsychopharmacology](#) 40 (S1): S397, 2015 (Invited speaker)
8. Oral Communication: *Ghrelin as a novel possible target to treat alcohol craving and role of endogenous serum levels as biomarker*. American Society of Clinical Psychopharmacology (ASCP), Scottsdale, AZ, June 2016
9. Presentation: *Mifepristone As A Pharmacological Intervention For Stress-Induced Alcohol Drinking*, Corcept Therapeutics Research Conference, San Francisco, CA November 2016 (Invited speaker)
10. Symposium: *Neuropsychoenocrine pathways in addiction*, American Association Addiction Psychiatry (AAP), Coconut Grove, FL December 2016; abstract in [American Journal on Addictions](#), 25(4): 310, 2016 (invited speaker)

11. Presentation: *Novel Approaches for Translational Research and Drug Discovery*. Society for Neuroscience, Session-III Mini-Convention Washington, DC
12. Presentation: *Expression of the functional C-terminus of Corticotropin Releasing Factor Binding Protein on the cell surface that enables a novel cell-based high-throughput screening assay* Sanford Burnham Prebys Medical Discovery Institute February 2018 (invited speaker)
13. Symposium: *Noradrenergic mechanisms at the intersection of alcohol dependence and stress* Research Society for Alcoholism (RSA), San Diego, CA, June 2018, abstract in Alcoholism: Clinical and Experimental Research, 42 (Suppl. S1), 72A, 2018 (discussant)
14. Symposium: *CRFR2 and CRFBP in CRF-induced potentiation of NMDR transmission in the VTA* 52nd Winter Conference on Brain Research, Snowmass, CO February, 2019 (Invited speaker)
15. Symposium: *Neuroendocrine and neuro immune mechanisms of addiction* 53rd Winter Conference on Brain Research, Big Sky, MT January 2020 (Invited speaker)
16. Symposium: *Cross-Species Evidence for Novel Therapeutic Targets in Alcohol Use Disorder: A phase 2 randomized cross-over drug-alcohol interaction study with the mGluR5 negative allosteric modulator GET 73 in individuals with alcohol use disorder*. Research Society for Alcoholism (RSA), New Orleans, LA June 2020, *Cancelled, carryover June 2021* (Invited speaker)
17. Symposium: *The stress of alcohol addiction-glucocorticoid receptors as an emerging drug target*, Research Society for Alcoholism (RSA), New Orleans, LA, 2020 June 2020, *Cancelled, carryover June 2021*, (Discussant)
18. Symposium on Substance Use Research, Rural Drug Research (RDAR), COBRE Opioid and Overdose, West Virginia Clinical and Translational Science Institute (WVCTSI): *Oxytocin to reduce stress-induced relapsing in patients with opioid use disorder*. November 2020, *Virtual* (Invited speaker)
19. Symposium: *Cross-Species Evidence for Novel Therapeutic Targets in Alcohol Use Disorder: A phase 2 randomized cross-over drug-alcohol interaction study with the mGluR5 negative allosteric modulator GET 73 in individuals with alcohol use disorder*. Research Society for Alcoholism (RSA), Austin, TX June 2021 (Invited speaker)
20. Symposium: *The stress of alcohol addiction-glucocorticoid receptors as an emerging drug target*, Research Society for Alcoholism (RSA), Austin, TX, June 2021 (Discussant)
21. Symposium: *Emerging Research on Addiction and Overdose. Oxytocin to reduce stress-induced opioid relapse: Human Laboratory Study*. Rhode Island IDEa Network of Biomedical Research Excellence (RI-INBRE), Virtual North East Regional IDEa Conference, August 2021
22. Presentation: *Randomized controlled trials for alcohol use disorder during the COVID-19 pandemic*. NIH, Translational Addiction Medicine Branch – NIDA IRP, October 20th, 2021
23. Symposium: *Peripheral Signals Suggest Central Targets for the Treatment of Drug and Alcohol Addiction: 54th Winter Conference on Brain Research*, Snowmass, CO February 2022 (Invited speaker, talk done by Joshua Brown, MD, PhD)
24. Symposium: *Glucocorticoid receptor antagonist for stress-induced alcohol craving: randomized clinical trial*. Yale NIAAA-T32 Translational Alcohol Research program and Yale-SCORE sex difference in alcohol use disorder. New Heaven, CT, February 2022 (Invited speaker)
25. Symposium: *Novel approaches targeting alcohol metabolism to treat alcohol use disorder*. Research Society for Alcoholism (RSA), Orlando, FL, June 2022 (Invited speaker, talk done by Roberta Perciballi, MD, post-doc)
26. Symposium: *Preclinical Models for Polysubstance Use and Multidrug Interactions*. Research Society for Alcoholism (RSA), Orlando, FL, June 2022 (Invited discussant, done by Falk Lehoff, PhD)
27. Presentation: *Mifepristone as a pharmacological intervention for stress-Induced alcohol craving: a translational randomized trial*. Corcept Therapeutics Research Conference, Halfmoon Bay, CA September 2022 (Invited speaker)

28. Symposium: *Take my stress away (from the amygdala): exploring the effects of alcohol on the CRF system outside traditional brain regions*. Research Society for Alcoholism (RSA), Bellevue, WA, June 2023 (Discussant)
29. Symposium: *Translational studies targeting noradrenergic receptors for AUD medication development: A cross-species, lifespan, and sex as biological variable perspective*. Research Society for Alcoholism (RSA), Bellevue, WA, June 2023 (Invited speaker)
30. Presentation: *Development of xylazine antidote*. Massachusetts Institute of Technology (MIT), Cambridge, MA, April 2024.
31. Presentation: *Development of xylazine antidote*. Brown Biomedical Innovations to Impact (BBII) Award, invited to present full proposal, May 2024.
32. Presentation: *Development of xylazine antidote*. Brown University Life Science Award, invited to present full proposal, June 2024.
33. Presentation: *Translational Neuroscience of Alcohol: Integration of Basic and Clinical Research*. Alcohol and the Nervous System Gordon Research Conference Feb 2024, Galveston, TX (Invited speaker)
34. Symposium: *Novel treatments for AUD: anti-inflammatory therapeutics and beyond*. Research Society for Alcoholism (RSA), Minneapolis, MN, June 2024 (Invited speaker)
35. Workshop: What is your best pitch? The values of entrepreneurship and startup creation training for substance use disorder researchers. The 87th Annual Scientific Meeting, College on Problem of Drug Dependence (CPDD), New Orleans, LA, 2025

INTERNATIONAL

36. Symposium: UNICAM, *Alcol a Nudo. A translational investigation on the role of Corticotropin Releasing Factor Binding Protein in alcohol consumption: a strange case of Dr. Jekyll and Mr. Hyde?* Università Camerino (UNICAM), Italy October 2016 (Invited speaker, cancelled due to earthquake)
37. Young Investigator Symposium: Volterra Conference *Alcoholism and Stress: A Framework for Future Treatment Strategies. Translational models to investigate allosteric modulation as strategy for small molecules as first-generation alcohol use disorder therapeutics*. Volterra, Italy, May 2017
38. Symposium: European Society for Biomedical Research on Alcoholism (ESBRA), Heraklion Greece. *Subgroups to predict pharmacotherapy response in Human Alcohol Laboratory Studies*, October 2017 (Invited speaker)
39. Presentation: Zardi – Gori Foundation Scientific Conference, *Alcohol Use Disorder: from Bench to Bedside, A translational approach for investigating stress-related alcohol use disorder*, Milan, Italy, November 2017 (Invited speaker)
40. Symposium: International Society for Biomedical Research on Alcoholism (ISBRA), Kyoto Japan: *Translational investigations on allosteric modulators (AM): Allosteric modulators targeting the corticotropin releasing factor* September 2018 (Chair and speaker)
41. Symposium: International Society for Biomedical Research on Alcoholism (ISBRA), Kyoto Japan. *Promising Targets of Alcohol Addiction: Promising Targets of Alcohol Addiction* September, 2018 (Invited speaker)
42. Symposium: European Society for Biomedical Research on Alcoholism (ESBRA), Lille, France: *The role of hormones in Alcohol Use Disorder* September, 2019, abstract in Alcoologie et Addictologie, 41 (3): 378, 2019 (Chair and speaker)
43. Symposium: European Society for Biomedical Research on Alcoholism (ESBRA), Lille, France: *Corticotropin releasing factor binding protein in the amygdala: the good, the bad and the ugly* September, 2019, abstract in Alcoologie et Addictologie, 41 (3): 378, 2019 (Chair and speaker)

44. Symposium: European Society for Biomedical Research on Alcoholism (ESBRA), Lille, France: *Medications with novel mechanisms for the treatment of alcohol use disorders* September 2019, abstract in *Alcoologie et Addictologie*, 41 (3): 378, 2019 (Chair and discussant)
45. Presentation: UNICAM University of Camerino, Italy. PhD talks: *Oxytocin to reduce stress-induced craving in patients with opioid use disorder*. November 2020, *Virtual* (Invited speaker)
46. Presentation: UNICAM University of Camerino, Italy. Talk Series: Un dottorando in 40 minuti - An initiative to keep going, Second Edition. *Pharmacotherapies for Alcohol Use Disorder the US and Europe*, February 2021 *Virtual* (Invited speaker)
47. Symposium: Volterra Conference *Alcoholism and Stress, Towards Personalized Treatment for Alcohol Use Disorder: Focus on α 1-blockade*. Volterra, Italy, May 2021 (Invited speaker, postponed due to COVID)
48. Presentation: UNICAM University of Camerino, Italy. PhD Talk Series: *PhD Updates and Research Accomplishments*, February 24th 2022 *Virtual*
49. Università Cattolica Sacro Cuore (UCSC), Rome, Italy. *Glucocorticoid receptors blockade as a pharmacological intervention for stress-Induced alcohol craving: a translational randomized trial*. September 29th 2022
50. Presentation: UNICAM University of Camerino, Italy. Neuroscience seminar series: *Neurofarmacologia dei farmaci d'abuso e sviluppo di terapie innovative della dipendenza da sostanze*, March 2023 (Invited Keynote speaker)
51. Symposium: Volterra Conference *Alcoholism and Stress, Glucocorticoids receptor antagonist for stress-induced alcohol reoccurrence*. Volterra, Italy, May 2023 (Invited speaker)

GRANTS

CURRENT GRANT SUPPORT

1. **R34 AA031589 (PI: Haass-Koffler)**
NIH/NIAAA
09/25/2024 – 09/24/2027
Direct Cost: \$449,998
Intranasal Insulin for treating Alcohol Use Disorder.
The goal of this clinical trial is to test the efficacy of IN insulin as a potential therapeutic for AUD. This study proposes a proof-of-concept, within-subject, crossover, double-blind, placebo-controlled human laboratory study with IN insulin compared to placebo in 40 non-treatment-seeking individuals with AUD. Role: Principal Investigator and IND Holder [IND168417; NCT05988632]
2. **Altimune (PI: Haass-Koffler)**
2/01/2025 – 2/01/2027
Award: Industry Sponsored
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects with Obesity or Overweight. The goal of this study is to test the efficacy and safety of GLP-1/glucagon dual receptor agonist in individuals with AUD and Obesity/overweight comorbidity.
Role: Principal Investigator
3. **Biomedical Innovations to Impact (BBII) (MPI: Haass-Koffler, McCance-Katz)**
Steven J. Massarsky Biomedical Research Innovation Award
6/21/2024 – 6/9/2025
Award: \$100,000
Development of an antidote for a fatal xylazine-laced overdose

The goal of this study is to test in the field the efficacy of an antidote that can reverse opioid overdose induced by drug laced with xylazine

Role: Principal Investigator

4. **IRX005603A (MPI: Eaton, Capone, Haass-Koffler)**

Providence VA Medical Center - Merit Grant

12/01/2024 – 11/30/2029

Direct costs: \$1,499,824

MDMA-Assisted Therapy for Veterans with PTSD and Alcohol Use Disorder, A Randomized Placebo-Controlled Trial

The goal of this clinical trial is to test the efficacy of MDMA-AT in 80 combat veterans with AUD and PTSD comorbidity.

Role: MPI and IND Holder

5. **R01 AA030888 (PI: Sheffler; Subaward PI: Haass-Koffler)**

NIH/NIAAA

09/21/2023 – 09/20/2028

Direct costs: \$3,500,000

Optimization of Drug-like Properties of CRFBP-CRF2 Negative Allosteric Modulators for Alcohol Use Disorder

This is a collaboration between Sanford Burnham Presby (PI: Sheffler), Brown University (Subaward PI: Haass-Koffler) and University of Camerino (Subaward PI: Cannella) for developing negative allosteric modulators (NAMs) that target the stress system.

Role: Principal Investigator Brown University Subaward

6. **R01 AA020990 (PI: Gunn)**

NIH/NIAAA

09/15/2023 – 09/14/2028

Direct costs: \$3,784,410

Effect of Cannabis Use on Alcohol Craving and Consumption among those in Alcohol Treatment

This project will examine how cannabis use impacts alcohol craving and consumption patterns among those early in alcohol treatment

Role: Co-I

7. **UE5 DA056914 (PI: Breazeal; Subaward PI: Haass-Koffler)**

NIH/NIDA

07/20/2022 – 07/19/2027

Direct costs: \$1,717,627

Program on Entrepreneurship and Innovation for Biomedical Product Development for Substance Use Disorder (SUD)

This is a collaboration between MIT (PI: Breazeal) and Brown (PI: Haass-Koffler) for developing of an academic program for biomedical and neuroscience researchers working in the field of substance use disorder (SUD) a first-of-its-kind, integrated curriculum on innovation, entrepreneurial problem solving and biomedical product development. Our program's goal is to promote technological and commercial innovations for SUD prevention, diagnosis and treatment.

Role: Principal Investigator Brown University Subaward (MIT primary)

8. **P20 GM130414 (Pilot MPI: Eaton and Capone)**

NIH/NIGMS

07/22/2022 - 07/21/2025

Direct costs: \$85,000

Evaluation of MDMA-assisted therapy in the central nervous system (CNS)

This study is evaluating MDMA-assisted therapy for the treatment of co-occurring posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) in combat veterans using peripheral biomarkers and MRI

Role: Mentor and IND MDMA Holder [IND165005; NCT05943665]

9. **Office of the Vice President Research (MPI: Haass-Koffler and Eaton)**

Brown University

02/22/2022 - 02/21/2024

Award: \$60,000

Safety, feasibility, and acceptability of MDMA-assisted therapy for the treatment of co-occurring posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) in combat veterans.

Role: Principal Investigator (MPI) and IND (MDMA) Holder [IND165005; NCT05943665]

10. **R01 AA027760 (PI: Haass-Koffler)**

NIH/NIAAA

09/10/2019 - 09/09/2024 (NCE)

Direct costs: \$2,460,664

A focus on $\alpha 1$ blockade as a novel pharmacological treatment for alcohol use disorder

The goal of this clinical trial is to understand the role of noradrenergic activation in alcohol use disorder (AUD) and identify endophenotypes to develop a precision medicine approach. To achieve these goals, this study proposes a 16 week, between-subject, double-blind, RCT with doxazosin compared to placebo.

Role: Principal Investigator [NCT04135846]

11. **R01 AA027760 Diversity Supplement (PI: Haass-Koffler)**

NIH/NIAAA

09/10/2019 - 09/07/2024

Direct costs: \$80,992

A focus on $\alpha 1$ blockade as a novel pharmacological treatment for alcohol use disorder

This diversity supplement is supporting a PhD student in neuroscience from an underrepresented minority and focuses on the mediation of the pro/anti-inflammatory processes on alcohol-related behaviors in individuals with AUD.

Role: Principal Investigator [NCT04135846]

12. **Research Excellence Award (PI: Haass-Koffler)**

Brown University: CAAS

06/21/2023 – 06/20/2025

Award: \$15,019

Intranasal Insulin for treating Alcohol Use Disorder

The goal of this application is to test the efficacy of IN insulin as a potential therapeutic for AUD. This study proposes a proof-of-concept, within-subject, crossover, double-blind, placebo-controlled human laboratory study with IN insulin compared to placebo in 10 non-treatment-seeking individuals with AUD.

Role: Principal Investigator and IND Holder [IND168417; NCT05988632]

PENDING GRANT SUPPORT

1. R01 AA031963 (PI: Haass-Koffler)

NIH/NIAAA

Status: impact score: 38, Resubmitted Nov 5th

04/01/2025– 03/31/2029

Direct costs: \$2,496,149

Probenecid for Alcohol Use Disorders

The goal of this application is to test the efficacy of probenecid in alcohol craving and consumption in a 12-week randomized controlled trial.

Role: PI Investigator and IND Holder

2. R21 DA062925 (PI: Haass-Koffler)
NIH/NIDA
Status: impact score: 47, To be Resubmitted March 16th
08/01/2025 – 07/31/2027
Direct costs: \$275,000
Intranasal Insulin for treating Cocaine Use Disorder
The goal of this application is to test the efficacy of IN insulin as a potential therapeutic for CUD. This study proposes a within-subject, crossover, double-blind, placebo-controlled human laboratory study with IN insulin compared to placebo in 24 individuals with CUD.
Role: Principal Investigator and IND Holder

3. Apollo (PI: Haass-Koffler)
8/01/2025 – 8/01/2027
Award: Industry Sponsored
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of APL-18881 for the Treatment of Alcohol Use Disorder (AUD). The goal of this study is to test the efficacy and safety of GLP-1 and a C-terminal fibroblast growth factor 21 (FGF21 dual receptor agonist in individuals with AUD.
Role: Principal Investigator

COMPLETED GRANT SUPPORT

1. R01 AA026589 (PI: Sheffler; Subaward PI: Haass-Koffler)
NIH/NIAAA
05/01/2019 – 03/31/2024
Direct costs: \$865,843
Lead optimization of novel CRFBP-CRFR2 complex modulators for alcohol use disorder
This is a collaboration between Sanford Burnham Prebys Medical Discovery Institute (PI: Sheffler) and Brown University (PI: Haass-Koffler). This project will develop CRF-BP/CRFR2 negative allosteric modulators (NAMs) using structure activity relationship (SAR) and electrophysiology for treating Alcohol Use Disorder
Role: Principal Investigator Brown University Subaward (SBP Primary)

2. R21 AA027614 (PI: Haass-Koffler)
NIH/NIAAA
04/10/19 – 03/31/2024 (NCE)
Direct costs: \$250,000
Probenecid as a pharmacotherapy for alcohol use disorder
After testing the role of pannexin 1 on operant oral alcohol self-administration in alcohol-dependent rats during acute withdrawal as well as in nondependent rats and in the drinking-in-the-dark (DID) paradigm of binge-like drinking in mice, this human laboratory study examines the alcohol-probenecid interaction in patients with alcohol use disorder
Role: Principal Investigator and IND (Probenecid) Holder [IND135570; NCT04051619]

3. P20 GM130414 (PI: Haass-Koffler)
NIH/NIGMS - COBRE Pilot
01/06/2019 – 12/30/2022
Direct costs: \$50,000

Oxytocin to reduce stress-induced craving in patients with opioid use disorder

This research examines the role of intranasal oxytocin on stress and cue-induced opioid craving in patients with opioid use disorder.

Role: PI and IND (oxytocin) Holder [IND135570; NCT04051619]

4. R21 AA027273 (PI: Jin)
NIH/NIAAA
09/10/2021 - 09/08/2023
Direct costs: \$224,250
Targeting stress reactivity, alcohol craving, and drinking with pioglitazone
This is a collaboration with the University of Texas, Health Science Center
Role: Collaborator
5. R01 AA024091 (PI: Metrik)
NIH/NIAAA
03/31/2016 – 03/31/2020
Direct costs: \$3,506,516
Marijuana's impact on alcohol motivation and consumption
The strategy of this proposal is to use the most comprehensive controlled test characterizing marijuana's putative effects on alcohol craving.
Role: Collaborator [IND129490; NCT02983773]
6. P20 GM130414 (PI: Monti; CLC project MPI: Haass-Koffler, Metrik)
NIH/NIGMS - Centers of Biomedical Research Excellence (COBRE)
01/01/2021 – 08/02/2022
Award: \$7,500
Rapid Response Award: The role of tetrahydrocannabinol in acute alcohol-induced inflammation. The strategy of this proposal is to examine the mediating role of cytokines as a mechanism whereby THC acutely decreases alcohol consumption.
Role: MPI [IND129490; NCT02983773]
7. Hanlon Foundation (MPI: Haass-Koffler, Kaun, McGeary, White)
Hubert & Richard Hanlon Trust Grant Award
08/01/2019 – 07/31/2022
Award: \$300,000
The Stress Factor: Understanding the role of norepinephrine in alcohol use disorder across species from fly to human. This study stemmed from the R01 AA027760 (PI: Haass-Koffler) and translates work from flies (*Drosophila*) to humans with the goal of understanding the how α 1-blockade (via doxazosin) affects the brain (fMRI) during stress conditions.
Role: Principal Investigator (MPI) [NCT04135846]
8. 5th \$10,000 Start a SUD StartupChallenge (PI: Murphy)
NIH/NIDA
06/23/2020 – 06/22/2021
Award: \$10,000
The Challenge goal is to support research ideas or technologies that would further an understanding of Substance Use Disorders (SUD) and will serve as a foundation for the development of successful new startups or products. We will develop a few candidate microspheres for limited in vitro data, to support a future SBIR application
Role: Co-investigator
9. K01 AA023867 (PI: Haass-Koffler)
NIH/NIAAA \$957,895

03/01/2016 – 02/28/2022

Mifepristone as a pharmacological intervention for stress-induced alcohol drinking

This project tests a preclinical paradigm, paired to a human alcohol laboratory model to investigate whether mifepristone, a glucocorticoid receptor antagonist, reduces alcohol craving and consumption

Role: Principal Investigator [IND121984; NCT02243709]

10. Rohsenow Pilot Project Award (PI: Haass-Koffler)
Brown University, CAAS
04/01/2020 – 03/31/2021
Award: \$2,000
Examining the impact of the rapidly evolving COVID-19 pandemic on individuals with AUD who have participated in human laboratory studies
This study evaluates longitudinally the effect of COVID-19 in the AUD population that have previously participated in human lab studies at CAAS. This study offers the unique opportunity to monitor in real time (by remote sessions) the effect of COVID-19 (e.g. isolation, stress, financial burden, risk) in a very clean sample where we have collected pre-COVID-19 data.
Role: Principal Investigator
11. P20 GM130414 (PI: Monti; PL: Haass-Koffler)
NIH/NIGMS - Centers of Biomedical Research Excellence (COBRE)
08/01/2019 – 10/01/2019
Direct costs: \$242,026
Oxytocin to reduce stress-induced craving in patients with opioid use disorder
This research examines the role of intranasal oxytocin on stress and cue-induced opioid craving in patients with opioid use disorder.
Role: Project Leader [IND135570; NCT04051619]
12. Rohsenow Pilot Project Award (PI: Haass-Koffler)
Brown University, CAAS
09/01/2017 – 08/30/2018
Award: \$2,490
Integrated cue-reactivity paradigm and eye tracking procedure to assess selective attention to simultaneous alcohol and smoking cues: a pilot study
This study will test a behavioral alcohol-smoking cue-reactivity paradigm paired with the use of the eye tracking procedure, to assess the preferred attention to alcohol or smoking cues in heavy-drinking smokers.
13. Laboratorio Farmaceutico CT S.r.l (PI: Swift)
06/01/2014 – 02/31/2018
Direct costs: \$535,714
A Phase Ib/IIa, cross-over, randomized, double-blind, placebo-controlled study to investigate the safety and pharmacodynamics effects of GET 73 in patients with alcohol use disorder
The aims of this research are: 1) to examine the safety of a glutamate modulator medication, GET 73 in combination with alcohol and 2) to determine if GET 73 reduces craving and alcohol consumption in non-treatment seeking alcohol-dependent subjects in an alcohol self-administration paradigm
Role: Co-Investigator
14. Research Excellence Award (PI: Haass-Koffler)
Brown University, CAAS
01/15/2014 – 06/14/2016
Award: \$15,000
Pilot Study on the safety and efficacy of mifepristone for the prevention of relapses of alcohol drinking
This study investigates the role of glucocorticoid receptor antagonist in alcohol use disorder

Role: Principal Investigator [IND121984; NCT02243709]

15. Strategic Opportunities Exploratory Award (PI: Haass-Koffler)
University of California, San Francisco (UCSF)
01/15/2012 – 06/14/2012
Award: \$5,000
Preclinical imaging study of Corticotropin Releasing Factor Binding Protein using 7T Magnetic Resonance Imaging (MRI)
Role: Principal Investigator

16. R21/33 DA029966 (PI: Cosford/Bartlett)
NIH/NIDA
2010 – 2012
Direct costs: \$423,032/\$487,500
Identifying Chemical Modulators of CRF-Binding Protein and CRF-Receptor Complexes for substance use disorder
This project combines novel cell-based assays (CRF-BP-CRF-R2 receptor complex), high throughput screening, structure activity relationship analysis, chemistry-based 'hit to lead' optimization to generate a targeted library of novel ligands and compounds
Role: Inventor (postdoc)

17. Molecular Libraries Small Molecule Repository (NIH/MLSMR) (PI: Bartlett)
NIH
2010 – 2012
The compounds in the NIH/MLSMR library will be screened using the Corticotropin Releasing Factor (CRF)-Binding Protein and CRF-Receptor Complexes
Role: Inventor (postdoc)

18. UCSF School of Pharmacy, Dean's Office and Clinical Pharmacy (PI: Haass-Koffler)
2009 – 2012
Training grant
Role: Fellow

INDUSTRY APPOINTMENTS AND PARTNERSHIPS

- 2002 - 2005 Roche Bioscience, Palo Alto, CA, Discovery Pharmaceuticals, Research Chemist, Research Associate II
- 2013 - pres. Corcept Therapeutics, pharmaceutical company developing products that regulate the effects of cortisol and deal with severe metabolic disorders, Menlo Park, CA
- 2016 - pres. Gravitas Bioscience, Inc, Providence, RI. Scientific Review Board
- 2016 - pres. Laboratorio Farmaceutico CT S.r.l, San Remo, Italy. Scientific Review Board
- 2025 - pres. Altimmune, PI multisite clinical trials

UNIVERSITY MENTORING AND TEACHING ROLES

MENTORING, SUPERVISING AND THESIS COMMITTEE ROLES

All undergraduates in the CNL take an Independent study (e.g. NEUR1970; CLPS1980), Senior Honor Thesis, and/or UTRA/SPRINT Research Award. See *addendum* for mentees accomplishments.

- 2013 – 2016 **Elie G Aoun, MD** Resident, Department of Psychiatry and Human Behavior, Alpert Medical School, Brown University (Mentor)
- 2015 – 2016 **Danielle E Giovenco, ScM, PhD**, Department of Behavioral and Social Science, School of Public Health, Brown University (Mentor and Supervisor)
- 2016 – 2017 **Sarah E Eltinge, ScB, AB**, School of Public Health, Brown University (Senior Honor Thesis Advisor)
- 2016 – 2018 **Rachel Souza, ScM**, Department of Behavioral and Social Science, School of Public Health, Brown University (Mentor and Thesis Advisor)
- 2016 – 2019 **Paul M Wallace, MD**, Medical Student Alpert Medical School, Brown University (Mentor)
- 2016 – 2019 **Kimberly Goodyear, PhD**, T-32 postdoctoral fellow, Department of Behavioral and Social Science, School of Public Health, Brown University (Mentor)
- 2016 – 2019 **Victoria M Long, ScM**, Department of Behavioral and Social Science, School of Public Health, Brown University (Mentor, Thesis Advisor and Supervisor)
- 2018 – 2020 **Bianca Persaud, AB/PLME** Brown Program Liberal Medical Edu (Mentor, Thesis Advisor and Supervisor)
- 2018 – 2019 **Robert Perciaballi, MD**, Internal Medicine and Toxicology and Experimental Therapeutics, La Sapienza University Rome Italy, Research Scholar (Mentor)
- 2019 – pres. **Zoe E Brown BS**, Center of Alcohol Addiction Studies, Brown University, Project Coordinator (Mentor and supervisor)
- 2020 – 2021 **Deena Haque, ScB candidate**, Neuroscience, Brown University (Mentor)
- 2020 – 2021 **Arianna Ferretti, ScB**, Neuroscience, Brown University (Mentor and Adviser for independent studies)
- 2020 – 2023 **Talia Vasaturo-Kolodner, ScB candidate**, Neuroscience, Brown University (Mentor)
- 2020 – 2023 **Dallece E Curley, PhD candidate**, Neuroscience, Brown University (Mentor and Thesis Advisor)
- 2021 – 2021 **Jeffery Rasmussen, PhD student**, Neuroscience, Brown University (Rotation Student)
- 2021 – 2022 **Liam Haass ScB candidate**, Neuroscience, Brown University (Mentor)
- 2021 – 2023 **Prahbjot Singh ScB candidate**, Neuroscience, Brown University (Mentor)
- 2021 – pres. **Morgan Nelson BS, ScM candidate**, Molecular Pharmacology, Physiology and Biotechnology, Brown University (Mentor and Thesis Advisor)
- 2021 – pres. **Brian Gully, MA**, Center of Alcohol Addiction Studies, Brown University, Research Assistant (Mentor and supervisor)
- 2021 – pres. **Ryan Rhew ScB candidate**, Neuroscience, Brown University (Mentor)
- 2021 – pres. **Paul Soliman ScB candidate**, Neuroscience, Brown University (Mentor)
- 2022 **Jamie Catalano, ScM**, PhD Candidate Molecular Pharmacology and Physiology Graduate Program, Brown University (Thesis Committee)
- 2022 – 2023 **Peter Sage ScB candidate**, Neuroscience, Brown University (Mentor)
- 2023 – pres. **Rivkah Hornbacher, PhD candidate**, Neuroscience, Brown University (Mentor)
- 2023 – pres. **Ifenna Amaefuna, ScB candidate**, Neuroscience, Brown University (Mentor)
- 2023 – pres. **Ramisa Fariha, PhD candidate**, Biomedical Engineering, Brown University (Mentor and Thesis Committee)
- 2023 -pres. **Daniella Furey, PhD, Psychology Resident**, VA Medical Center (co-Mentor)
- 2024 **Marcel Schaack BS**, MBA candidate MIT Slone School of Management (Mentor)
- 2024 **Meray Nemr, ScB candidate**, Neuroscience and School of Public Health, Brown University (Mentor)
- 2024 **Reyner Jusuf, BS, ScM candidate**, Biotechnology, Brown University (Mentor, Thesis Advisor)

- 2024 – pres. **Eric Miller, MD, Psychiatry Resident**, Brown University (co-Mentor)
- 2024 – pres. **Emma Pecogne, PhD, Psychology Resident**, Brown University (co-Mentor)
- 2024 **Danusha Selva Kumar, PhD, Postdoctoral Fellow** Coro Center, Brown University, Diversity, Equity, Inclusivity and Belongingness (DEIB) Program (mentor)
- 2024 – pres. **Stephanie Foster, MD, PhD, Psychiatry Resident**, Brown University (co-Mentor)

FACULTY MENTOR

- 2021 – pres. **Christy Capone, PhD**, Assistant Professor, Department of Psychiatry and Human Behavior, Brown University
- 2021 – pres. **Erica Eaton, PhD**, Assistant Professor, Department of Psychiatry and Human Behavior, Brown University
- 2021 – 2024 **Joshua Brown, MD, PhD**. Assistant Professor, Director of the TMS facilities, McLellan Hospital, Harvard University
- 2024 **Wendy Samter, PhD**, Professor, Dept. Communication and Language Studies, Bryant University National Science Foundation (NSF) project: *Igniting New Federal Research Applications*
- 2025 – pres. **John Hernandez, PhD**, Assistant Professor (Research) of Neuroscience, Brown University, project: Brain Science's COBRE Center for Central Nervous System Function (CNSF) Pilot Project Award.

CONFERENCE MENTOR

- 2021 **Jorge Avila PhD, Rutgers University**, 60th American College Neuropsychopharmacology (ACNP), Travel Awardee (Mentor)
- 2022 **Luis Colon-Perez, PhD, University of North Texas Health Science Center**, 61st American College Neuropsychopharmacology (ACNP), Travel Awardee, Mentor
- 2023 **Jude Frie, PhD Candidate, University of Guelph**, Winter Brain Research Conference (WBRC), Travel Awardee, Mentor
- 2024 **Leili Mortazavi, BS PhD candidate, Stanford University**, Research Society for Alcohol (RSA) Mentor
- 2024 **Ana Deutsch, PhD, University of Calgary**, 63rd American College Neuropsychopharmacology (ACNP), Mentor

MENTOR AND TEACHING TRAINING PROGRAM

- 2019 Center for AIDS Research (CFAR) Mentor-the-Mentor Certification, NIH National Research Mentoring Network (NRMN)
- 2020 Advance-CTR Clinical Translational Research and Brown University, *Obtain K awards and transition to the R series Advance-K Scholars program*
- 2023 Brown University, Karen T. Romer Undergraduate Teaching and Research Awards (UTRAs) Faculty Mentoring Learning Community Sessions: Mentoring, Mentoring Models
- 2023 Massachusetts Institute of Technology (MIT) J-WEL Course Design Workshop. This is an interactive workshop where you will have the chance to work on your course while being introduced to examples of course design, and tools to help you build a quality learning experience for your students
- 2024 – pres. Brown University, BioMed Office of Graduate Studies Mentor Training: *Curriculum* from the Center for Improvement of Mentored Experiences in Research (CIMER). (Sessions: Diversity & Inclusion, Culturally Aware Mentoring; What if conflicts or issues arise?)

2025 – pres. Brown University, Department of Psychiatry Human Behavior, NIMH-Funded R25 Research Training Program (RTP) Mentor

TEACHING

ACADEMIC TEACHING ROLE

- 1999 University of Minnesota, Twin Cities, College Science & Engineering, *Chemistry and Material Science in the conservation of mural paintings*, lecture for development of scientific approaches using chemistry and material science in mural paintings (25 graduate students in the Chemistry and Chemical Engineering programs)
- 2000 University of California, Berkeley, School of Chemistry, *The role of Chemistry in Art Conservation*, lecture for development of scientific approaches using chemistry for the authentication of easel paintings, (150 undergraduate and graduate students in the Chemistry and Chemical Engineering programs)
- 2001 University of California, Berkeley, School of Chemistry, *From Chemistry Student to Research Chemist in Pharmaceuticals*, message to entering student at the University of California, Berkeley, (100 undergraduates and transfer students)
- 2007 University of California, Berkeley, School of Public Health, *Pharmacy and Pharmaceutical Science Pathway, a new avenue for pharmacists to perform research* (125 undergraduates)
- 2006 - 2007 University of California, San Francisco (UCSF), School of Pharmacy, *Physiopathology of Addiction*, organized and administered series of lectures as UCSF Drug Abuse Awareness Coordinator for the California Society of Health-Systems Pharmacists on the physiopathology of addiction of drugs of abuse. Lectures included: the abuse of dextromethorphan, GHB rape drug, and presentation of a recovering addict pharmacist (120 UCSF Pharm.D. students and faculty)
- 2009 University of California, San Francisco (UCSF), School of Pharmacy, *Corticotropin Releasing Factor Binding Protein in the CNS*, Pharmaceutical Sciences Pathway Project presentation
- 2009 - 2012 University of California, San Francisco (UCSF), School of Medicine, Seminar Series, Clinical Pharmacology and Experimental Therapeutics for approximately (3-10 Clinical fellows, MD, PhD and PharmD)
- 1) *HLA-B*5701 genotype: major determinant of drug-induced liver injury due to flucloxacillin*
 - 2) Principles Clinical Pharmacol, *Cardiovascular Safety of Medications treatment for ADHD*
 - 3) Principles Clinical Pharmacol, *System pharmacology: Inflammation/Immunomodulation*
 - 4) *Neurotransmitters: Use in clinical practice as biomarkers of nervous system function*
 - 5) *Pharmacokinetics: Drug-Drug interactions*
- 2009 - 2012 University of California, San Francisco, Gallo Center, Neuroscience, Microscopy and Visualization: Lecturer and technical support for the Neuroscience Department, (50 students, graduate, postdocs, faculty)
- 1) *Imaris Neuroscience microscopy/software interface*
 - 2) *In vivo Microscopy: applications in Neuroscience*
- 2009 - 2012 University of California, San Francisco, Gallo Center, Neuroscience, Medications Development Group, Mentor for rotating students: undergraduate (UC Berkeley and Merritt College), graduate and pharmacy (Touro University and UCSF) students
- 2010 University of California, San Francisco, School of Medicine, *Corticotropin Releasing Factor Binding Protein in the CNS*, Clinical Pharmacology and Experimental Therapeutic, Quarterly Research Seminars

2010	University of California, San Francisco, Gallo Center, <i>In vivo Microscopy: applications in Neuroscience workshop</i> , Headland Institute, CA
2010	University of California, San Francisco, Gallo Center, <i>A novel approach to characterize the role of Corticotropin Releasing Factor Binding Protein in the CNS</i>
2010	University of California, San Francisco, School of Medicine, Clinical Pharmacology and Experimental Therapeutics Fellows' Quarterly Research Seminar. <i>Molecular Characterization of Corticotropin Releasing Factor-Binding Protein</i> .
2010 - 2011	University of California, San Francisco, School of Pharmacy, Pharmaceutical Sciences Pathway seminar series: <i>From Pharmaceutical Science student to UCSF fellow</i> , lecture for Pharm.D. students interested in performing research under a faculty advisor across multiple schools, (3-10 third year PharmD students) in the Winter quarter each year
2011 - 2012	University of California, San Francisco, School of Pharmacy, Pharmacokinetic and Biopharmaceutical: coordinating and administering lectures and workshop for second year PharmD students in Drug-Drug interaction, lectures, workshop (120 PharmD students) in the Fall/Winter quarter each year
2011	University of California, San Francisco, Gallo Center. <i>Molecular Characterization of Corticotropin Releasing Factor-Binding Protein</i> .
2013	Brown University, Center Alcohol and Addiction Studies. <i>Stress as Discrete Biobehavioral Approach in Alcohol Use Disorder. Knowledgebase, CAAS, Brown University, Providence, RI</i>
2013	Northeastern University, Bouvé College of Health Science, Pharmaceutical Science <i>Pharmacogenomics</i> , Three-hour lecture lectures within the Pharmacokinetics/Pharmacodynamics course for Pharmaceutical Science and Biotechnology (66 M.S. and PhD students)
2013 – 2021	Northeastern University, Bouvé College of Health Science, Pharmacy School, <i>Pharmacogenomics</i> , six lectures within the Pharmacology and Medicinal Chemistry II (157 PharmD students), in the Summer each year
2014 – 2015	Northeastern University, Bouvé College of Health Science, Pharmaceutical Science, <i>Drug Discovery and Development of Medications for treating Drug Dependence & Addictions</i> . Lecture within Drug Discovery course, (50 MS and PhD students), in the Fall each year
2015 – pres.	Brown University, T32 Core Seminar Series, CAAS, <i>Ethics: Intellectual Properties</i> . Butler Hospital, (30 Clinical Psychology and T-32 Postdoctoral fellows)
2016 – pres.	Brown University, T32 Core Seminar Series, CAAS, <i>Psychosocial and Pharmacologic Treatment of Substance Use Disorders: Pharmacological Treatment for Addictions: the example of Alcohol Use Disorder from Experimental Therapeutics perspective</i> , (T-32 Postdoctoral fellows)
2017 – pres.	Brown University, T32 Core Seminar Series, CAAS, <i>Etiology of Substance Abuse: The role of stress on substance use, craving and relapse</i> (T-32 Postdoctoral fellows)
2018	Research Society for Alcoholism (RSA): 1) <i>Skill Blitz session</i> , host a round table (graduate/post-baccalaureate trainees) 2) <i>NIAAA and the RSA Education Committee workshop</i> , facilitator “Getting Your First Research Grant” breakout, and a “Career Development Award” Breakout (postdocs and junior investigators)
2019 – 2021	Brown University, School of Public Health: Pharmacological approaches for Alcohol Use Disorder in the <i>Alcohol Use and Misuse Course</i> SPH1540
2020	Brown University, <i>COBRE Retreat: Oxytocin to reduce stress-induced craving in patients with opioid use disorder. Brown University, Virtual</i>
2020	Brown University, <i>COBRE Retreat: Oxytocin to reduce stress-induced craving in patients with opioid use disorder. Brown University, Virtual</i>

2020 – 2021	Brown University, T32 Core Seminar Series, CAAS, <i>Grant Writing Series: The Approach Section</i> (T-32 Postdoctoral fellows)
2023 – pres.	Massachusetts Institute of Technology (MIT), <i>Program on Entrepreneurship and Innovation for Biomedical Product Development: Substance Use disorder 123</i> (Fellows)
2024	Brown University, Alpert Medical School, Anesthesiology Grand Round: <i>Substance Use Disorder of Anesthesia</i> (Attending anesthesiologists, Nurse anesthetists, and Residents)
2024	Massachusetts Institute of Technology (MIT), Seminar: <i>Identifying public health needs to create new Substance Use Disorder therapies</i> (Fellows)
2024	Brown University, School of Public Health: <i>Responsible Conduct of Research</i> (PhD Students)
2024	Brown University, Alpert Medical School: Elective on Addiction Medicine (Medical Students)
2025	Brown University, Department of Psychiatry and Human Behavior, <i>Clinical Trials Design and Methodology</i> (Psychiatry Residents)

HOSPITAL TEACHING ROLES

1994 - 1995	Red Cross, Assistant in the training of International Humanity Law for Army Military and Red Cross Officers (50 military personnel)
1994 - 1995	Red Cross, Qualified Counselor of International Humanity Law, Marina di Massa, 1994. Assistant in the training of International Humanity Law for Army Military and Red Cross Officers (50 military personnel)
1994	Italian Air Force, School Medicine, Rome. Lieutenant in charge training nurses' qualification Air Mobile Search & Rescue (SAR), (30 military personnel)

ADDENDUM: MENTORING AND SUPERVISING ROLES

All undergraduates in the CNLab take an Independent study (e.g. NEUR1970; CLPS1980), Senior Honor Thesis, and/or are the recipients of an UTRA/SPRINT Research Award

**MENTEES ACCOMPLISHMENTS IN THE CLINICAL NEUROSCIENCE LABORATORY
AND THEIR CURRENT POSITION**

(Post-doctoral Fellows, Residents, Graduate Students, Medical Students and Undergraduate Students)

Position in the Clinical Neuroscience Laboratory	Trainee	Role	Year	Achievements in the Laboratory	Position after the Clinical Neuroscience Laboratory
Psychiatry Resident Alpert Medical School	Elie G Aoun, MD	Mentor	2013 2016	<ul style="list-style-type: none"> • 2014 - American Academy of Addiction Psychiatry (AAP), Aventura, FL; Poster Recipient: 9th highest score out of 200 submissions and Travel Award • 2015 - AAP, Huntington Beach, CA; Poster Selected: for Medscape Report • 2015 - R25 Grant Awardee for the Brown University Psychiatry Training Research Track, National Institute of Mental Health (R25MH101076) • 2016 - American Association of Directors of Psychiatric Residency Training (AADPRT), International Medical Graduate award • 2016 - AAP American Psychiatric Leadership Award • 2016- 2018 - AAP Associate Chair Program Committee • 2016 - 2017 - APA – SAMSHA Substance Abuse and Minority Fellowship awardee, APA • 2016 - Stepping Up National Summit/APEX (American Psychiatric Excellence Award) Travel Award, APA, 2016 • 2016 - AADPRT International Medical Graduate Award, AADPRT • 2016 - 2017 Addiction Psychiatry Fellow, University California, San Francisco, CA • 2017-2019 -Forensic Psychiatry Fellow, Columbia University, NY • 4 publications 	Columbia University Assistant Professor
ScM candidate Class 2016 Research Assistant Behavioral Social Sciences	Danielle E Giovenco, ScM, PhD	Mentor Supervisor	2015 2016	<ul style="list-style-type: none"> • 2016 - Graduated MSc, Behavioral Social Science, School Public Health • 2017 - PhD Candidate, Epidemiology, Gillings School of Global Public Health, University North Carolina • 1 publication 	Assistant Professor Emory University
ScB/AB candidate Class 2017 School Public Health	Sarah E Eltinge, ScB, AB	Senior Honor Thesis Advisor	2016 2017	<ul style="list-style-type: none"> • 2017 - Award for Excellence in Public Health Honors Thesis • 2017 - Sc.B. Statistics & A.B. Public Health • 2017 - Selected for the Brown School of Public Health highlights SPH student story • 2017-2019 - Johnson & Johnson Health Technology Center, Research Analyst, Providence, RI • 1 publication 	Analytics Engineer III American Civil Liberties Union
ScM candidate Class 2019 Behavioral Social Sciences	Rachel Souza, ScM	Mentor Thesis Advisor	2016 2018	<ul style="list-style-type: none"> • 2017 - Accepted to Master program, Behavioral Social Science, School Public Health, Brown University • 2018 - NIH/NIAAA Research Society for Alcoholism, Student Merit Award • 1 publication 	Philadelphia College of Osteopathic Medicine
MD candidate Class 2019 Alpert Medical School	Paul M Wallace, MD	Mentor	2016 2019	<ul style="list-style-type: none"> • 2016 - Alpert Medical School, Brown University Summer Assistantship • 2016 - Summer Institute for Medical Students (SIMS), Hazelden Betty Ford Foundation • 2017 - Society of Teachers of Family Medicine Conference on Medical Student Education, Naloxone in the homeless community project, Anaheim, CA, travel funded by SAMSHA • 1 publication 	Psychiatry Residency University California San Francisco (UCSF)
T-32 Postdoctoral Fellow Behavioral Social Sciences	Kimberly Goodyear, PhD	Mentor IND Holder	2016 2019	<ul style="list-style-type: none"> • 2016 - Research Society of Alcoholism (RSA) Student Merit Award • 2017 - NIH/NIAAA Travel Award Volterra Conference, Italy • 2017 - ASCP Clinical Trials Workshop Fellowship, NY • 2017 - RSA Junior Investigator Award 	Assistant Professor CAAS Behavioral Social

				<ul style="list-style-type: none"> • 2017 - Research Excellence Award, NCATS-funded partnership to collaborate among early-career scholars to focus on Radical Solutions to the Opioid Misuse Epidemic • 2019 - K01 AA026874 <i>The Neural Mechanisms Associated With Alcohol and Cigarette Craving in AUD Smokers During Oxytocin Treatment</i> • 2019 -1st Price Postdoctoral Poster Award, Brain Mind, Brown • 9 publications 	Sciences School of Public Health Brown University
ScM candidate Class 2019 Research Assistant Behavioral Social Sciences	Victoria M Long, ScM	Mentor Supervisor	2016 2019	<ul style="list-style-type: none"> • 2019 - Graduate ScM Behavioral Social Science School Public Health, Brown University • 2019 - Recipient of the Public Health Impact Award • 2020 - Selected Article: ACER Article of Public Interest (API) • 7 publications 	Research Associate Cengage
ScB candidate Class 2020 Neuroscience	Harrison H Tran	Mentor	2016 2018	<ul style="list-style-type: none"> • 2017 - Karen T. Romer Undergraduate Teaching and Research Award (UTRA) • 2012 - Admitted to Harvard and University California, San Francisco (UCSF) Medical School • 3 publications 	University California San Francisco (UCSF) Medical School
Brown Program Liberal Medical Edu (PLME) AB and MD	Bianca Persaud, AB	Mentor Honors Thesis Advisor	2018 2020	<ul style="list-style-type: none"> • 2020 - Public Health Honors Thesis • 2020 - Graduated AB Public Health 	Warren Alpert Medical School Brown University
Research Scholar	Roberta Perciballi, MD	Mentor	2018 2019	<ul style="list-style-type: none"> • 2019 - Residency Program Internal Medicine and Toxicology and Experimental Therapeutics, La Sapienza University, Rome Italy • 3 publications 	ASL Center for Treating Dependencies
ScB candidate Class 2021 Neuroscience	Arianna Ferretti	Mentor	2020 2021	<ul style="list-style-type: none"> • 2020 - BrownConnect Collaborative SPRINT Award (Projects for Research, Internships, and Teaching), 2020 	Research Assistant RI Hospital
T-32 Postdoctoral Fellow	Samantha Portis, PhD	Mentor	2020 2021	<ul style="list-style-type: none"> • 3 publications • 2023 - NIH/NIAAA K99 Award: <i>Metadoxine for Alcohol Use Disorder</i> 	CAAS Brown University
Research Scholar	Wooyoung Jung, MD, PhD	Mentor	2020 2021		Psychiatrist South Korea, Hospital
ScB candidate Class 2023 Neuroscience	Deena Haque	Mentor	2020 2021	<ul style="list-style-type: none"> • 2021 - Bonner Community Fellowship 	
PhD candidate Class 2024 Neuroscience	Jeffery Rasmussen ScM	Rotation student	2021		Harvard Medical School
ScB candidate Class 2023 Neuroscience	Liam Haas	Mentor	2021		
ScM candidate Class 2022 Biotechnology	Morgan Nelson, MSc	Mentor Honor Thesis Advisor	2021 2022	<ul style="list-style-type: none"> • 2022 - Poster at the Brown University SPH Research Day • 2022 – Honor Thesis: <i>Disruption of Circadian Rhythms Promotes Alcohol Use</i> • 1 publication 	
ScB candidate Class 2023 Neuroscience	Talia Vasaturo-Kolodner	Mentor Honor Thesis Advisor	2020 2023	<ul style="list-style-type: none"> • 2022 - BrownConnect SPRINT UTRA in Fall <i>Hormones and Alcohol Use Disorder: A Secondary Analysis to Elucidate Therapeutic Targets</i> (\$1,200) • 3 publications • 2023 - Invited interviews for PhD Neuroscience: Oxford University, King's College, UCLA and Brown • 2023 – Nominate Undergraduate Neuroscience Award For Excellence in Academics and Research 	Oxford's Dphil Neuroscience programme
PhD candidate Class 2023 Neuroscience	Dallece Elena Curley, BS	Thesis Mentor	2020 2023	<ul style="list-style-type: none"> • 2021 - Science Mentoring & Diversity Program Biotechnology Program (SMDP) Award • 2021 - Submitted NIH/NIAAA Diversity Supplement • 2020-2021 - NSGP Graduate Student Council (GSC) Representative • 2021 - Teaching Assistant for Experimental Neurobiology with Dr. John Stein • 2021-2022 - GSC Finance Committee • 2021-2022 - NSGP Seminar Speaker Series Graduate Student Representative • 2021-2022 - Serving on the Graduate Labor Organization Grievance Committee • 2021 - Society for Neuroscience's (SfN) Neuroscience Scholars Program (NSP) Associate Fellow 	Eli Lilly Pharmaceutical Company

				<ul style="list-style-type: none"> • 2021 Brown University International Travel Award for Studying at the University of Camerino, Italy • 2021 - NIAAA Diversity Supplement • 2021 - American Society of Microbiology, Judge for the ABRCM Conference • 2021 - Certificate from The Foundations of Clinical Research Program, Harvard Medical School • 2021 - K α τ Foundation Award Jeanne Ross Miller Grant Endowment • 2022 - Brown University International Travel Award for Studying at the University of Camerino, Italy • 2022 - Janssen Pharmaceuticals (Johnson & Johnson) Preclinical Sciences & Translational Safety Co-op • 4 publications (1 in preparation) • Job offer Harvard Medical School and Ely Lilly Pharmaceutical company 	
ScB candidate CLPS Class 2024	Peter Sage	Mentor	2022 2023	<ul style="list-style-type: none"> • 2022 - CLPS 1980: Independent Study - <i>Empathy and Addiction Independent Study</i> 	
ScB candidate Class 2023 Neuroscience	Prabhjot Singh	Mentor	2021 2023	<ul style="list-style-type: none"> • 2022 - BrownConnect SPRINT UTRA in Fall <i>Strategies for Overcoming Barriers to AUD Clinical Trial Recruitment and Retention</i> (\$1,200) • School of Medicine Mt. Sinai, Flex Med Program 	School of Medicine Mt. Sinai
ScB candidate Neuroscience Class 2024	Ryan Rhew	Mentor Honor Thesis Advisor	2021 2024	<ul style="list-style-type: none"> • 2022 - BrownConnect SPRINT UTRA <i>Presence of sensitization in clinical alcohol cue-reactivity assessments: a secondary analysis</i> (\$1,600) • 2022 - Selected to present at the Brown University Fall Elevator Pitch event • 2022 - NEUR 1970: Independent Study – <i>Phenotypic differences in patients with AUD</i> • 2023 - NEUR 1970#2: Independent Study – <i>Phenotypic differences in patients with AUD in alcohol cue-reactivity response</i> • 2023 - Mind Brain Research Day, Brown University • 2023 - BrownConnect SPRINT UTRA Summer <i>Preclinical models for AUD, University of Camerino, Italy</i> (\$6,500) • 3 publications • Honors Thesis 	
ScB candidate Neuroscience Class 2024	Paul Soliman	Mentor	2021 2024	<ul style="list-style-type: none"> • 2022 - BrownConnect SPRINT UTRA in Fall <i>Placebo Use in Clinical Trials with Psychedelics</i> (\$1,200) • 2022 - NEUR 1970: Independent Study - <i>Placebo Use in Clinical Trials with Psychedelics</i> • 2023 - Research at Brown (RAB) Award (\$400) to conduct Research at the University of Camerino, Italy • 2023 - Royce Fellowship (\$4,500) • 3 publications • 2023 - NEUR 1970: Independent Study – Systematic Review on the use of <i>Placebo Use in Clinical Trials with Psychedelics</i> 	School of Medicine, Vanderbilt University
ScB candidate Neuroscience Class 2024	Ifenna Amefuna	Mentor	2023 2024	<ul style="list-style-type: none"> • 2023 - NEUR 1970: Independent Study – <i>Alcohol use disorder clinical readability</i> • 2023 - The Pediatric Oncology Education program (PAE) at St. Jude Children's Research Hospital: 2023 Summer Internship, Memphis, TN • 1 publication 	
MBA Candidate MIT Sloane	Marcel Schaack	Mentor	2024	<ul style="list-style-type: none"> • Project Xylazine 	
PhD Candidate Biomedical engineering	Ramisa Fariha	Mentor and Thesis Committee	2023 2024	<ul style="list-style-type: none"> • 1 publication (under review) 	Brown RNA Center
MPH Candidate	Alexis Friedman	Second Mentor for Thesis	2023 2024	<ul style="list-style-type: none"> • poster 	
MPH Candidate	Maryna Rasputna	Second Mentor for Thesis	2023 2024	<ul style="list-style-type: none"> • poster 	
Project Coordinator MPH Program	Zoe E Brown, MPH	Mentor Supervisor	2019 2024	<ul style="list-style-type: none"> • 2021 - Nominated for the SPH Staff Excellence Award in Innovation • 3 publications • 2022 - School of Public Health Staff Advisory Committee (SAC) • 2022 - Accepted to the MPH program Brown and Boston University • 2023 – School of Public Health Research Day Poster 	Columbia University

				<ul style="list-style-type: none"> • 2023 – Sweaner Center, Engaged Research Mini-Grant • 2023 – Inter. Ass. Research Service-Learning, Community Engagement Conference 	
Psychology Resident VAMC	Daniella Furey, PhD	Mentor	2023 2024	<ul style="list-style-type: none"> • Involvement in the MDMA study 	Clinical psychologist the Bedford VAMC

CURRENT MEMBERS IN THE CLINICAL NEUROSCIENCE LABORATORY

Position in the Clinical Neuroscience Laboratory	Trainee	Role	Year	Achievements in the Laboratory
Research Assistant	Brain Gully, MA	Mentor Supervisor	2021 pres	<ul style="list-style-type: none"> • 2022 - Dept. Psychiatry RA Research Day, Fall. Poser presentation: <i>Lessons Learned in running studies with patients for Opioid Use Disorder</i> • 3 publications
PhD candidate Neuroscience Class 2028	Rivkah Hornbacher	Mentor	2022 pres	<ul style="list-style-type: none"> • 2022 semester rotation • 2023 semester rotation • 2023 CNLab member and doctoral student • 3 publications (1 in preparation)
ScM candidate Biotechnology Class 2026	Reyner Jusuf, BS	Mentor	2024	<ul style="list-style-type: none"> • Project communalization of an antidote for fatal opioid overdose • Presentation Brown VC Café • Support for the MIT Entrepreneurship Project
ScB candidate Neuroscience Class 2027	Yoyo Zhang	Mentor	2024 pres	<ul style="list-style-type: none"> • Spring 2025 UTRA Award
ScB candidate Health/Human Biology Class 2028	Leeah Han	Mentor	2024 pres	<ul style="list-style-type: none"> •
ScB candidate Neuroscience and Public Health Class 2027	Meray Nemr	Mentor	2024 pres	<ul style="list-style-type: none"> • 2024 - NEUR 1970: Independent Study – <i>Alcohol use disorder and chronic psychosomatic pain</i>
Psychology Resident Brown University	Emma Pecogne, PhD	Mentor	2024 pres	<ul style="list-style-type: none"> • Involvement in the MDMA study
Psychiatry Resident Brown University	Eric Miller, MD	Mentor	2024 pres	<ul style="list-style-type: none"> • Involvement in the MDMA study • CNS Drug Manuscript in preparation
Psychiatry Resident Brown University	Stephanie Foster, MD, PhD	Mentor	2024 pres	<ul style="list-style-type: none"> • Involvement in the xylazine study
MPH Program Brown University	Lauren Ranney	Mentor	2024 pres	<ul style="list-style-type: none"> • Practicum: developing active placebo for MDMA randomized clinical trial
PLME AB'28, MD'32	Lee Broderick	Mentor	2024 pres	<ul style="list-style-type: none"> •
MPH Program University of North Carolina	Isabelle Katz	Mentor	2025 pres	<ul style="list-style-type: none"> • Data Analyst

FACULTY MENTORSHIP

Name	Year	Achievements	Current position
Joshua C Brown, MD, PhD	2021 pres	<ul style="list-style-type: none"> • Co-I in three clinical protocols • 2023 ACNP – Travel Award 	Assistant Professor and Director

		• 1 publication (2 under review)	Dept. Psychiatry, Harvard Medical School McLellan Hospital, TMS
Erica Eaton, PhD	2021 pres	• CADRE and OVPR Award (MDMA Study) • MPI in one clinical protocol • 2 publications (1 under review)	Assistant Professor Providence VA Medical Center Dept. Psychiatry and Human Behavior, Brown University
Christy Capone, PhD	2021 pres	• CADRE and OVPR Awards (MDMA Study) • MPI in one clinical protocol • 2 publications (1 under review)	Assistant Professor Providence VA Medical Center Dept. Psychiatry and Human Behavior, Brown University
Wendy Sammter, PhD	2024	• NSF Project: Igniting New Federal Research Application	Professor Dept. Communication and Language Studies Bryant University
John Hernandez, PhD	2025	• COBRE Project Mentor	

LIST OF POSTERS WITH MENTEES (*Mentee)

NATIONAL

1. Aoun EG*, Haass-Koffler CL, Swift RM, Addolorato G, Kenna GA, and Leggio L. *The Significance of Thyroid Hormones as Biomarkers for Prognosis and Baclofen Treatment Response in Alcohol Dependent Patients*, Mind Brain Research Day, Brown University, Providence, RI, 2014
2. Aoun EG*, Haass-Koffler CL, Swift RM, Addolorato G, Kenna GA, and Leggio L. *The Significance of Thyroid Hormones as Biomarkers for Prognosis and Baclofen Treatment Response in Alcohol Dependent Patients*, American Psychiatric Association Annual Meeting, New York, NY, 2014
3. Aoun EG*, Haass-Koffler C, Swift RM, Addolorato G, Kenna GA, and Leggio L. *The Role of Aldosterone and Cortisol in Alcohol Use Disorders in a Baclofen Treatment Study*. American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Hollywood, FL, 2014
4. Aoun EG*, Haass-Koffler CL, Swift RM, Addolorato G, Kenna GA, and Leggio L. *The Role of Aldosterone and Cortisol in Alcohol Use Disorders in a Baclofen Treatment Study*, American Academy of Addiction Psychiatry (AAAP), Aventura, FL, 2014
5. Haass-Koffler CL, Aoun EG*, Kenna GA, de la Monte SM, Swift RM, and Leggio L. *Exogenous intravenous ghrelin administration decreases endogenous serum leptin level and increases alcohol craving*. Research Society of Alcoholism (RSA), San Antonio, TX, 2015
6. Haass-Koffler CL, Aoun EG*, Kenna GA, de la Monte SM, Swift RM, and Leggio L. *Exogenous intravenous ghrelin administration decreases endogenous serum leptin level and increases alcohol craving*. American Academy of Addiction Psychiatry (AAAP), Huntington Beach, CA, 2015 abstract in *American Journal on Addictions*, 25(4): 310, 2016, Selected: for Medscape Report
7. Haass-Koffler, CL, DE Giovenco*, PM Wallace*, Henry AT, * Melkus G, Simms JA, Naemmuddin M, Nielsen CK, Schwandt ML, Lasek A, Magill M, Momenam R, Hodgkinson CA, Bartlett SE, Swift RM, Bonci A, Leggio L. *In vitro, in vivo and human investigations on the role of Corticotropin Releasing Factor Binding Protein in alcohol consumption*, Mind Brain Research Brown University, Providence, RI, 2016
8. Haass-Koffler CL, DE Giovenco*, PM Wallace*, Zywiak, W, Kenna GA, de la Monte SM, Swift RM, and Leggio L. *Ghrelin a Novel Possible Target to Treat Alcohol Craving and Role of Endogenous hormones Serum Levels as Biomarker*, Mind Brain Research Brown University, Providence, RI, 2016
9. Haass-Koffler CL, DE Giovenco*, Wallace PM*, Zywiak, W, Kenna GA, de la Monte SM, Swift RM, and Leggio L. *Ghrelin a Novel Possible Target to Treat Alcohol Craving and Role of Endogenous hormones Serum Levels as Biomarker*, 56th American Society Clinical Psychopharmacology (ASCP), Scottsdale, AZ, 2016, Selected: for Oral Presentation
10. Haass-Koffler, CL, Henry AT*, Melkus G, Simms JA, Naemmuddin, Nielsen CK, Schwandt ML, Lasek A, Magill M, Momenam R, Hodgkinson CA, Bartlett SE, Swift RM, Bonci A, Leggio L. *In vitro, in vivo and*

- human investigations on the role of Corticotropin Releasing Factor Binding Protein in alcohol consumption*, Research Society of Alcoholism (RSA), New Orleans, LA, 2016 abstract in Alcoholism: Clinical and Experimental Research, 40 (Suppl. S1), 139A
11. Haass-Koffler CL, Giovenco DE*, Zywiak, W, Kenna GA, de la Monte SM, Swift RM, and Leggio L. *Endogenous Intravenous Ghrelin Administration Decreases Endogenous Insulin and Increased Alcohol Craving*, Research Society of Alcoholism (RSA), New Orleans, LA, 2016, abstract in Alcoholism: Clinical and Experimental Research, 40 (Suppl. S1), 139A
 12. Haass-Koffler CL, Giovenco DE*, Zywiak WH, McGeary J, Kenna GA, de la Monte SM, Leggio L, Swift RM L. *Aripiprazole and Topiramate on Free-Choice Alcohol Use and Exploratory Pharmacogenetics*, Research Society of Alcoholism (RSA), New Orleans, LA, 2016, abstract in Alcoholism: Clinical and Experimental Research, 40 (Suppl. S1), 139A
 13. Wallace PR*, Haass-Koffler CL, Goodyear K*, Zywiak WH, Magill M, Eltinge SE*, Jayaram-Lindström N, Swift RM, Kenna GA, Leggio. *Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin*. Warren Alpert Medical School Summer Showcase, Brown University, Providence RI, November 2016
 14. Haass-Koffler, CL, Henry AT*, Melkus G, Simms JA, Naemmuddin, Nielsen CK, Schwandt ML, Lasek A, Magill M, Momenam R, Hodgkinson CA, Bartlett SE, Swift RM, Bonci A, Leggio L. *In vitro, in vivo and human investigations on the role of Corticotropin Releasing Factor Binding Protein in alcohol consumption*, 55th American College on Neuropsychopharmacology (ACNP), Hollywood, FL, 2016, abstract in Neuropsychopharmacology 41 (S1): S629, 2016
 15. Eltinge SE*, Goodyear K*, Chavanne D, Wallace PM*, Long VM*, Swift RM, Leggio L and Haass-Koffler CL. *Demand inelasticity and higher demand intensity on the Alcohol Purchase Task is associated with greater reduction in drinking in patients with Alcohol Use Disorder*, Mind Brain Research Day, Brown University, Providence, RI, 2017
 16. Long VM*, Goodyear K*, Loche L, Cacciaglia R, Swift RM, Leggio L and Haass-Koffler CL, *Safety, tolerability and pharmacokinetics of the mGluR5 negative allosteric modulator GET73 following single and repeated doses in healthy volunteers*. Mind Brain Research Day, Brown University, Providence, RI, 2017
 17. Long VM*, Goodyear K*, Loche L, Cacciaglia R, Swift RM, Leggio L and Haass-Koffler CL, *A phase 1 randomized cross-over drug-alcohol interaction study with the mGluR5 negative allosteric modulator GET 73 in healthy male volunteers*. Mind Brain Research Day, Brown University, Providence, RI, 2017
 18. Long VM*, Goodyear K*, Loche L, Cacciaglia R, Swift RM, Leggio L and Haass-Koffler CL, *A phase 1 randomized cross-over drug-alcohol interaction study with the mGluR5 negative allosteric modulator GET 73 in healthy male volunteers*. School of Public Health Research Day, Brown University, Providence, RI, 2017
 19. Haass-Koffler CL, Goodyear K*, Eltinge SE*, Wallace PM*, Long VM*, Cacciaglia R, Swift RM, Leggio L. *Safety, tolerability, pharmacokinetics and bioavailability of GET73 and its metabolite MET2*. Research Society of Alcoholism (RSA), Denver, CO, 2017 abstract in Alcoholism: Clinical and Experimental Research, 41 (Suppl. S1), 218A, 2017
 20. Goodyear K*, Haass-Koffler CL, Eltinge SE*, Chavanne D, Wallace PM*, Long VM*, Swift RM, Leggio L. *Intensity of Alcohol Demand as a Moderator of Alcohol Drinking in Alcohol-Dependent Individuals Treated with Doxazosin*. Research Society of Alcoholism (RSA), Denver, CO, 2017, 2017 abstract in Alcoholism: Clinical and Experimental Research, 41 (Suppl. S1), 218A, 2017
 21. Tran HH*, Goodyear K*, Farokhnia M, Swift RM, Leggio L and Haass-Koffler CL, *Analysis of endogenous hormones in alcoholic smokers*, Brown University, Providence, RI, Summer Research Symposium, 2017
 22. Haass-Koffler CL, Francis CT*, Sheffer DJ, Naemmuddin M, Nilsen CK, Bartlett SE, Swift RM, Leggio L, N Cosford NDP and Bonci A. *Development of Corticotropin Releasing Factor Binding Protein allosteric modulators*. 56th American College on Neuropsychopharmacology (ACNP), Palm Spring, CA 2017, Neuropsychopharmacology 43 (S1): S456, 2017

23. Haass-Koffler CL, Francis CT*, Sheffer DJ, Naemmuddin M, Nilsen CK, Bartlett SE, Swift RM, Leggio L, N Cosford NDP and Bonci A. *Development of Corticotropin Releasing Factor Binding Protein allosteric modulators*. Gordon Conference, Galvaston, TX 2018
24. Souza RD*, Wilmott J*, Long VM*, Goodyear K*, Magill M, Swift RM, Song JH, Haass-Koffler CL. *Integrated cue-reactivity paradigm to assess selective attention to simultaneous alcohol and smoking cues: a pilot study*. Mind Brain Research Day Brown University, RI 2018
25. Long VM*, Goodyear K*, Swift RM, Leggio L and Haass-Koffler CL, *Ghrelin effects on endogenous serum cortisol and aldosterone levels in alcohol dependent individuals*. Mind Brain Research Day Brown University, RI 2018
26. Tran HH*, Long VM*, Goodyear K*, Leggio L, Haass-Koffler CL. *Preliminary analysis for correlation between oxytocin, endogenous stress hormones and opioid hormone in alcoholic smokers*. Mind Brain Research Day Brown University, RI 2018
27. Wilmott J*, Souza RD*, Song JH, Haass-Koffler CL *Selective attention predicts choice behavior in heavy drinking smokers*. School Public Health, Research Day Brown University, RI 2018
28. Souza RD*, Wilmott J*, Long VM*, Goodyear K*, Magill M, Swift RM, Song JH, Haass-Koffler CL. *Integrated cue-reactivity paradigm to asses selective attention to simultaneous alcohol and smoking cues: a pilot study*. School Public Health, Research Day Brown University, RI 2018
29. Tran HH*, Long VM*, Goodyear K*, Leggio L, Haass-Koffler CL. *Preliminary analysis for correlation between oxytocin, endogenous stress hormones and opioid hormone in alcoholic smokers*. School Public Health, Research Day Brown University, RI 2018
30. Souza RD*, Wilmott J*, Long VM, Goodyear K*, Magill M, Swift RM, Song JH, Haass-Koffler CL. *Integrated cue-reactivity paradigm to asses selective attention to simultaneous alcohol and smoking cues: a pilot study*. RSA, San Diego, CA, 2018, abstract in Alcoholism: Clinical and Experimental Research, 42 (Suppl. S1), 72A, 2018
31. Long VM*, Goodyear K*, Swift RM, Leggio L and Haass-Koffler CL, *Ghrelin effects on endogenous serum cortisol and aldosterone levels in alcohol dependent individuals*. Research Society for Alcoholism (RSA), San Diego, CA, 2018, abstract in Alcoholism: Clinical and Experimental Research, 42 (Suppl. S1), 72A, 2018
32. Goodyear K*, Chavanne D, Long VM*, Souza RD*, Swift RM, Leggio L, Haass-Koffler CL. Substance use and stigmatizing attitudes. Poster presented at the 2018 Research Society on Alcoholism (RSA), San Diego, CA. June 16-20, 2018; abstract in Alcoholism: Clinical and Experimental Research, 42 (Suppl. S1), 72A, 2018
33. Haass-Koffler CL, Long VM*, Farokhnia M, Kenna GA, Swift RM, Leggio L. *Intravenous administration of ghrelin increases blood cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind placebo-controlled human laboratory study*. Poster presented at the 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL. December 8-13, 2017; abstract in Neuropsychopharmacology 43 (S1): S139, 2018
34. Souza RS*, Willmott J*, Long VM, Goodyear K*, Son J, Swift RM, Magill M, Aston E, Haass-Koffler CL. *Integrated Cue-Reactivity Paradigm to Assess Selective Attention to Simultaneous Alcohol and Smoking Cues: A Pilot Human Laboratory Study*. Mind Brain Research Day/Public Health Research Day, Brown University, Providence, RI, 2019
35. Perciballi R*, Persaud B*, Leggio L, and Haass-Koffler CL, *Effects of smoking on endogenous hormones in individuals with alcohol use disorder*. Mind Brain Research Day/Public Health Research Day, Brown University, Providence, RI, 2019
36. Long VM*, Farokhnia M, Magill M, Kenna GA, Swift RM, Leggio L, Haass-Koffler CL. *Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: results from a double-blind, placebo-controlled human laboratory study*. Mind and Brain Research Day, Brown University, Providence RI, 2019.
37. Persaud B*, Perciballi R*, Leggio, L, and Haass-Koffler CL, *Effects of smoking on endogenous hormones in individuals with alcohol use disorder*. Public Health Research Day, Brown University, Providence, RI, 2019

38. Goodyear K*, Swift RM, Leggio L and Haass-Koffler CL, *Neural responses to alcohol cues in heavy-drinking smokers*. Mind Brain Research Day, Brown University, Providence, RI, 2019.
39. Long VM*, Piacentino D*, Li X, Leggio L, Haass-Koffler CL. *Comparing non-treatment-seeking participants in alcohol medication research studies across demographic and clinical variables by geographic location*. School of Public Health Research Day, Brown University, Providence RI, 2019
40. Perciballi R*, Ceccanti N; Attilia ML; Swift RM and Haass-Koffler CL *Case report: "If...you hear hoof beats behind you, don't look back expecting to see a zebra. Expect a horse" (Theodore Woodward). The horse case: Alcohol Use Disorder and Dilated Cardiomyopathy*. Public Health Research Day, Brown University, Providence, RI, 2019
41. Goodyear K*, Swift RM, Leggio L and Haass-Koffler CL, *Neural responses to alcohol cues in heavy-drinking smokers*. Public Health Research Day, Brown University, Providence, RI, 2019
42. Goodyear K*, Swift RM, Leggio L and Haass-Koffler CL, *Neural responses to alcohol cues in heavy-drinking smokers*. 4th International Conference on Applications of Neuroimaging to Alcoholism (ICANA-4) Yale University, New Haven, CT, 2019
43. Haass-Koffler CL, Piacentino D*, Long VM, Li X, Lee M, Kenna GA, Swift RM, Leggio L. *Demographic and clinical differences between treatment-seeking and non-treatment-seeking participants in medication studies to treat alcohol use disorder*. Poster presented at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Orlando, FL. December 8-11, 2019; abstract in *Neuropsychopharmacology* 44(Suppl. S1), S256, 2019
44. Brown ZE*, Piacentino D*, Perciballi R*, Li X, Long VM*, Swift RM, Leggio L, Haass-Koffler CL. *Treatment-seeking versus non-treatment-seeking research participants in predicting the outcome of alcohol use disorder treatments: The role of their sociodemographic and alcohol-related characteristics*. Public Health Research Day, Brown University, Providence, RI, April 6, 2020, *Virtual due to COVID-19 pandemic*
45. Portis SM*, Gonsavales M, Brown ZE*, Vasaturo-Kolodner T*, Ferretti A*, Fleig C, Mc Geary J, Zywiak WH, Leggio L, White T, Haass-Koffler CL, *Characterization of Alpha-1 Receptors Expression in Individuals with Alcohol Use Disorder*. Poster presented at the 59th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), December 2020 *Virtual due to COVID-19 pandemic*
46. Munivar A*, Haass-Koffler CL, Wu R, Kenna GA, O'Malley SS, Leggio, L. *Metadoxine Reduces Alcohol Consumption in a Double-Blind, Placebo-Controlled, Pilot Study in Patients with Alcohol Use Disorder*. Poster presented at the 59th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), December 2020, *Virtual due to COVID-19 pandemic*
47. Goodyear K*, Vasaturo-Kolodner T*, Leggio L, Kenna GA, Swift RM and Haass-Koffler CL. *Changes in alcohol-related behaviors and characteristics from the baseline to the randomization session for participants with alcohol use disorder*. School of Public Health Research Day, Brown University, April 2021
48. Curley DE*, Brown ZE*, Vasaturo-Kolodner T*, Cannella N, Swift RM, Ciccocioppo R and Haass-Koffler CL. *Sex difference in the effect of yohimbine on alcohol-related behaviors* School of Public Health Research Day, Brown University, April 2021
49. Portis SM*, Sun H, Leggio L and Haass-Koffler CL. *Increased amygdala expression of receptors alpha-1B in postmortem brain of individuals with alcohol use disorder*. School of Public Health Research Day, Brown University, April 2021
50. Ferretti A*, Curley DE*, Portis SM*, Quintana A, Brown ZE*, Fleig C, Swift RM and Haass-Koffler CL. *The impact of COVID-19 pandemic on alcohol-related behaviors in individual with Alcohol Use Disorder*. School of Public Health Research Day, Brown University, April 2021
51. Goodyear K*, Vasaturo-Kolodner T*, Leggio L, Kenna GA, Swift RM and Haass-Koffler CL. *What is the true baseline session? A comparison of changes in alcohol-related characteristics from screening to randomization in treatment and non-treatment seekers*. Research Society for Alcoholism (RSA), San Antonio, TX, 2021
52. Curley DE*, Brown ZE*, Vasaturo-Kolodner T*, Cannella N, Swift RM, Ciccocioppo R and Haass-Koffler CL. *Sex difference in the effect of yohimbine on alcohol-related behaviors*. Research Society for Alcoholism (RSA), San Antonio, TX, 2021

53. Portis SM*, Sun H, Leggio L and Haass-Koffler CL. *Increased amygdala expression of receptors alpha-1B in postmortem brain of individuals with alcohol use disorder*. Research Society for Alcoholism (RSA), San Antonio, TX, 2021
54. Haass-Koffler CL, Perciballi R*, Magill M, Colombo GC, Loche A, Cacciaglia R, Swift RM, and Leggio L. *Alcohol-drug interaction studies from preclinical to human laboratory studies: evaluation of a metabotropic glutamate receptor subtype 5 (mGluR5) as a pharmacotherapy for Alcohol Use Disorder* Poster submitted to the 60th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Porto Rico. December 8-11, 2021
55. Nelson MJ*, Soliman P*, Rhew R*, Haass-Koffler CL, *Disruption of Circadian Rhythms Promotes Alcohol Use*. School of Public Health Research Day, Brown University, April 2022
56. Haass-Koffler CL *Mifepristone as a pharmacological intervention for stress-Induced alcohol craving: a translational randomized trial*. The 61st Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Phoenix, AZ. December 4-10, 2022
57. Brow, ZE*, Haass-Koffler CL *Mifepristone as a pharmacological intervention for stress-Induced alcohol craving: a translational randomized trial*. School of Public Health Research Day, April 4th 2023
58. Rhew R*, Leggio L, Swift RM and Haass-Koffler CL. *Phenotypic differences in patients with AUD in alcohol cue-reactivity response*. Mind Brain Research Day, Brown University, Providence, RI, 2023
59. Gully B*, Brown ZE*, Brown JC, Swift RM and Haass-Koffler CL, *Intranasal Oxytocin as a Pharmacological Intervention for Stress-Induced Opioid Withdrawal: A Human Laboratory Study*, The 62nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Tampa Bay, FL. December 3-6, 2023
60. Gully BJ, Brown ZE, Capone C Eaton E, Swift RM, Haass-Koffler CL. *Design and methodology of the first open-label trial of MDMA-Assisted Therapy for Veterans with PTSD and AUD*. School of Public Health Research Day, Brown University, April 2024
61. Rasputna M, Dorval C, Brown ZE, Haass-Koffler CL, Ziobrowski HN, *The impact of psychiatric Comorbidities on Alcohol Use Disorder Treatment Complexion*, School of Public Health Research Day, Brown University, April 2024
62. Frieadman A, Dorval C, Brown ZE, Haass-Koffler CL, Ziobrowski HN, *The impact of psychiatric Comorbidities on Opioid Use Disorder Treatment Complexion*, School of Public Health Research Day, Brown University, April 2024
63. Yoon JH, Lane SD, Schmitz JM, Haass-Koffler CL, Dang V, Ochiam L, Vincent JN, Suchting R, de Dios C. *Effects of the social cold pressor task on stress reactivity and alcohol craving and demand*. Abstract submitted for presentation at the annual meeting for the College on Problems of Drug Dependence, Montreal, ON, Canada. 2024
64. Hornbacher R#, Brown ZE#, Gully BJ#, Cioe P, Swift RM, Sanna PP, Haass-Koffler CL, *Probenecid and alcohol interaction on hormonal and inflammatory response: Examining sex-specific effects*, Research Society for Alcohol (RSA), Minneapolis, MN, 2024
65. Capone C*# Eaton E*#, Brown ZE#, Gully BJ#, Hornbacher R#, MWarden M, Swift RM, Haass-Koffler CL. *Design and methodology of the first open-label trial of MDMA-Assisted Therapy for Veterans with PTSD and AUD*. Research Society for Alcohol (RSA), Minneapolis, MN, 2024
66. Hornbacher R*, Brown JC, Swift RM and Haass-Koffler CL, *Oxytocin reduces noradrenergic-induced opioid-like withdrawal symptoms in individuals on opioid agonist therapy*. The 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Phoenix, AZ. December 4-9, 2024
67. Shankar K, ... Haass-Koffler CL, Cosford N, Sheffler D, *Development of Novel Negative Allosteric Modulators of CRFBP-CRF2 for Substance Use Disorders*. The 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Phoenix, AZ. December 4-9, 2024
68. Yoon JH, Lane SD, Schmitz JM, Weaver MF, Haass-Koffler CL, Dang V, Ochiam L, Vincent J, Suchting R, de Dios C. *Effect of Pioglitazone on Stress Reactivity and Stress-Induced Craving*, College on Problems of Drug Dependence (CDPP), New Orleans, 2025
69. Ranney L, Gully B, Capone C, Eaton E, Swift RM, Haass-Koffler CL. *Optimizing Active Placebo for MDMA randomized controlled Trials*. Public Health Research Day, School of Public Health, Brown University, April 2025

INTERNATIONAL

70. Haass-Koffler CL, Kenna GA, Henry AT* and Bartlett SE. *Altered binge-like ethanol consumption in corticotropin releasing factor binding protein-deficient mice*, European Society for Biomedical Research on Alcoholism (ESBRA), Warsaw, Poland, 2013, abstract in Alcohol and Alcoholism, 48(Suppl. 1): i4, 2013
71. Haass-Koffler CL, Aoun EG*, Kenna GA, de la Monte SM, Swift RM, and Leggio L. *Exogenous intravenous ghrelin administration decreases endogenous serum leptin level and increases alcohol craving*. European Society for Biomedical Research on Alcoholism (ESBRA), Valencia, Spain, 2015, abstract in Alcohol and Alcoholism, 50(Suppl. 1): i56, 2015
72. Goodyear K*, Haass-Koffler CL, Zywiak WH, Magill M, Wallace PR, Eltinge S, Jayaram-Lindström N, Swift RM, Kenna GA, Leggio. *Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin*. Alcoholism and Stress: A Framework for Future Treatment Strategies, Volterra, Italy, 2017 abstract in Alcohol, 60 (P119): 222-223, 2017
73. Haass-Koffler CL, Souza RD*, Wilmott J*, Long VM*, Goodyear K*, Magill M, Song JH, Swift RM. *Integrated cue-reactivity paradigm and eye-tracking paradigm to assess selective behavior and selective attention to simultaneous alcohol and smoking cues*. International Society for Biomedical Research on Alcoholism (ISBRA), Kyoto, Japan, 2018
74. Perciballi R*, Long VM*, Piacentino D, Li X, Leggio L, Haass-Koffler CL. *Comparing non-treatment-seeking participants in alcohol medication research studies across demographic and clinical variables by geographic location*. European Society for Biomedical Research on Alcoholism (ESBRA), Lille, France, 2019, abstract in Alcoologie et Addictologie, 41 (3): 378, 2019
75. Persaud B*, Perciballi R*, Leggio, L, and Haass-Koffler CL, *Effects of smoking on endogenous hormones in individuals with alcohol use disorder*. European Society for Biomedical Research on Alcoholism (ESBRA), Lille, France, 2019, abstract in Alcoologie et Addictologie, 41 (3): 378, 2019
76. Goodyear K*, Swift RM, Leggio L and Haass-Koffler CL, *Neural responses to alcohol cues in heavy-drinking smokers*. European Society for Biomedical Research on Alcoholism (ESBRA), Lille, France, 2019, abstract in Alcoologie et Addictologie, 41 (3): 378, 2019